



Belgian Cancer Registry

CANCER FACT SHEET 2024

COLORECTAL CANCER

ICD-10 C18-C20



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from the Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. For colorectal cancer, stage IV means the cancer has spread to other organs. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

- **Clinical stage:** Stage based on clinical examinations (e.g.: medical imaging, biopsies) to estimate the extent of the tumour. Clinical stage is established before the start of any treatment.
- **Pathological stage:** Stage based on pathological examinations of the tumour after surgery. **Pathological stage without neo-adjuvant therapy** is the pathological stage in the population that did not receive neo-adjuvant therapy prior to surgery. **Pathological stage after neo-adjuvant therapy** is the pathological stage in the population that did receive neo-adjuvant therapy prior to surgery. Pathological stage regardless of neo-adjuvant therapy is reported as (y)pStage.
- **Neo-adjuvant therapy (NAT):** Treatment (e.g.: chemotherapy/radiotherapy) given prior to surgery, with the goal to shrink the tumour before operating.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE	5
1.1. Colorectal cancer incidence: by region	5
1.1.1. Colorectal cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024.....	5
1.2. Colorectal cancer incidence: by tumour stage	7
1.2.1. Colorectal cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024	7
1.2.2. Colorectal cancer incidence by pathological stage ((y)pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024.....	7
1.2.3. Colorectal cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024.....	8
1.2.4. Colorectal cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024.....	9
1.2.5. Rectal cancer incidence by stage variables, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024.....	10
2. CANCER INCIDENCE TRENDS	11
2.1. Colorectal cancer incidence trends: by region.....	11
2.1.1. Colorectal cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024.....	11
2.1.2. Colorectal cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024.....	13
2.2. Colorectal cancer incidence trends: by tumour stage	14
2.2.1. Colorectal cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards...	14
2.3. Colorectal cancer incidence trends: by age group.....	16
2.3.1. Colorectal cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024.....	16
2.3.2. Colorectal cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024.....	17
3. CANCER PREVALENCE	18
3.1. Colorectal cancer prevalence: by region.....	18
3.1.1. Colorectal cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024.....	18
4. CANCER SURVIVAL.....	19
4.1. Colorectal cancer survival: by region	19
4.1.1. Colorectal cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024.....	19
4.2. Colorectal cancer survival: by sub-location and tumour stage	21
4.2.1. Colorectal cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024	21
4.2.2. Colorectal cancer survival by sub-location, pathological stage ((y)pStage) and sex: number at risk and net survival probabilities, 2015-2024.....	23

4.2.3. Colorectal cancer survival by sub-location, stage and sex: number at risk and net survival probabilities, 2015-2024	25
5. CANCER SURVIVAL TRENDS.....	27
5.1. Colorectal cancer survival trends: by tumour stage.....	27
5.1.1. Colorectal cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024	27
5.2. Colorectal cancer survival trends: by sub-location and tumour stage.....	29
5.2.1. Colorectal cancer survival trends by sub-location, stage and sex: number at risk and net survival probabilities, 2004-2024	29
6. CANCER MORTALITY	32
6.1. Colorectal cancer mortality: by region.....	32
6.1.1. Colorectal cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023	32
7. CANCER MORTALITY TRENDS.....	34
7.1. Colorectal cancer mortality trends: by region	34
7.1.1. Colorectal cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023	34
7.1.2. Colorectal cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023	36
7.2. Colorectal cancer mortality trends: by age group	37
7.2.1. Colorectal cancer mortality* trends in males, by age group: number of new diagnoses, crude and age-standardised mortality rates, including average annual percentage change, 2004-2024	37
7.2.2. Colorectal cancer mortality* trends in females, by age group: number of new diagnoses, crude and age-standardised mortality rates, including average annual percentage change, 2004-2024	38

1. CANCER INCIDENCE



1.1. Colorectal cancer incidence: by region

1.1.1. Colorectal cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

N [CR]																						ESR2013 (95%CI)	
Region	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages		
Males																							
Belgium	0	0	5	1	6	10	15	48	90	103	236	325	464	568	659	670	486	370	132	15	4,203	76.4	
	[0.0]	[0.0]	[1.4]	[0.3]	[1.7]	[2.7]	[3.8]	[12.6]	[23.3]	[27.6]	[60.1]	[81.5]	[122.1]	[174.8]	[245.3]	[314.6]	[384.0]	[450.4]	[404.9]	[235.3]	[72.5]	(74.1; 78.8)	
Brussels	0	0	0	0	1	1	2	8	14	14	29	30	33	44	31	49	34	18	4	2	314	76.3	
	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[1.9]	[3.8]	[16.8]	[30.7]	[31.8]	[70.3]	[82.8]	[111.7]	[202.3]	[182.5]	[380.7]	[413.3]	[355.4]	[178.2]	[355.2]	[51.3]	(67.6; 85.1)	
Flanders	0	0	4	1	4	7	9	26	48	66	126	163	274	313	404	366	312	262	75	11	2,471	71.9	
	[0.0]	[0.0]	[2.0]	[0.5]	[2.1]	[3.5]	[4.1]	[12.2]	[21.6]	[31.0]	[55.8]	[68.3]	[117.9]	[155.9]	[243.2]	[271.0]	[372.5]	[471.1]	[342.9]	[261.3]	[73.2]	(69.1; 74.8)	
Wallonia	0	0	1	0	1	2	4	14	28	23	81	132	157	211	224	255	140	90	53	2	1,418	85.5	
	[0.0]	[0.0]	[0.9]	[0.0]	[0.9]	[1.8]	[3.4]	[11.8]	[23.9]	[19.7]	[64.4]	[106.9]	[133.0]	[206.2]	[261.9]	[392.1]	[405.2]	[419.4]	[625.0]	[124.7]	[78.5]	(81.0; 90.0)	
Females																							
Belgium	0	0	5	8	13	6	33	44	80	95	202	197	322	414	547	519	504	438	177	32	3,636	55.3	
	[0.0]	[0.0]	[1.5]	[2.4]	[3.9]	[1.7]	[8.4]	[11.5]	[20.7]	[25.7]	[52.4]	[50.2]	[83.4]	[120.0]	[183.2]	[202.7]	[289.8]	[323.2]	[245.7]	[148.1]	[60.9]	(53.5; 57.1)	
Brussels	0	0	0	0	2	0	4	6	13	11	22	15	23	34	48	46	38	32	13	2	309	59.7	
	[0.0]	[0.0]	[0.0]	[0.0]	[4.6]	[0.0]	[7.3]	[12.3]	[28.6]	[26.3]	[57.1]	[43.6]	[75.3]	[135.2]	[222.9]	[248.1]	[296.7]	[331.6]	[230.4]	[95.3]	[48.5]	(53.0; 66.5)	

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	3	3	8	4	15	20	43	49	103	109	173	206	262	281	315	288	120	20	2,022	50.1
	[0.0]	[0.0]	[1.6]	[1.6]	[4.4]	[2.0]	[6.9]	[9.3]	[19.3]	[23.2]	[46.5]	[46.8]	[74.7]	[99.7]	[147.9]	[181.6]	[287.4]	[332.0]	[265.0]	[155.3]	[58.7]	(47.9; 52.4)
Wallonia	0	0	2	5	3	2	14	18	24	35	77	73	126	174	237	192	151	118	44	10	1,305	63.6
	[0.0]	[0.0]	[1.8]	[4.6]	[2.7]	[1.9]	[11.8]	[15.0]	[20.3]	[29.9]	[61.4]	[58.3]	[101.9]	[153.8]	[237.3]	[232.0]	[293.3]	[301.4]	[208.5]	[150.7]	[69.2]	(60.1; 67.1)

1.2. Colorectal cancer incidence: by tumour stage

1.2.1. Colorectal cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-74	75+	All ages 0+		15-49	50-74	75+	All ages 0+	
I	44 [1.7]	502 [28.4]	336 [72.9]	883 [15.2]	16.0 (14.9; 17.0)	41 [1.6]	361 [20.0]	277 [42.0]	681 [11.4]	10.4 (9.6; 11.2)
II	29 [1.1]	343 [19.4]	349 [75.8]	721 [12.4]	13.3 (12.3; 14.3)	40 [1.6]	260 [14.4]	356 [54.0]	656 [11.0]	9.7 (9.0; 10.5)
III	87 [3.4]	546 [30.9]	326 [70.8]	960 [16.6]	17.3 (16.2; 18.4)	63 [2.5]	410 [22.7]	375 [56.9]	848 [14.2]	12.9 (12.1; 13.8)
IV	59 [2.3]	438 [24.8]	311 [67.5]	808 [13.9]	14.7 (13.6; 15.7)	61 [2.4]	339 [18.8]	341 [51.7]	741 [12.4]	11.3 (10.5; 12.2)
X/NA	54 [2.1]	423 [24.0]	351 [76.2]	831 [14.3]	15.2 (14.2; 16.3)	74 [2.9]	312 [17.3]	321 [48.7]	710 [11.9]	10.9 (10.1; 11.7)

1.2.2. Colorectal cancer incidence by pathological stage ((y)pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

(y)pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-74	75+	All ages 0+		15-49	50-74	75+	All ages 0+	
I	64 [2.5]	657 [37.2]	370 [80.3]	1,093 [18.9]	19.6 (18.5; 20.8)	56 [2.2]	458 [25.3]	300 [45.5]	818 [13.7]	12.7 (11.9; 13.6)
II	59 [2.3]	454 [25.7]	439 [95.3]	955 [16.5]	17.5 (16.4; 18.6)	68 [2.7]	386 [21.4]	470 [71.3]	925 [15.5]	13.9 (13.0; 14.8)
III	63 [2.4]	499 [28.3]	338 [73.4]	900 [15.5]	16.3 (15.3; 17.4)	66 [2.6]	388 [21.5]	378 [57.4]	832 [13.9]	12.7 (11.8; 13.6)
IV	28 [1.1]	135 [7.6]	82 [17.8]	245 [4.2]	4.4 (3.9; 5.0)	38 [1.5]	119 [6.6]	93 [14.1]	250 [4.2]	3.9 (3.4; 4.4)
X/NA	59 [2.3]	507 [28.7]	444 [96.4]	1,010 [17.4]	18.5 (17.4; 19.7)	51 [2.0]	331 [18.3]	429 [65.1]	811 [13.6]	12.0 (11.2; 12.9)

1.2.3. Colorectal cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-74	75+	All ages 0+		15-49	50-74	75+	All ages 0+	
I	60 [2.3]	633 [35.9]	398 [86.4]	1,093 [18.9]	19.7 (18.5; 20.9)	57 [2.2]	450 [24.9]	322 [48.9]	833 [14.0]	12.9 (12.0; 13.8)
II	53 [2.0]	466 [26.4]	481 [104.4]	1,003 [17.3]	18.5 (17.3; 19.7)	69 [2.7]	371 [20.5]	490 [74.3]	931 [15.6]	13.9 (13.0; 14.8)
III	87 [3.4]	650 [36.8]	406 [88.1]	1,143 [19.7]	20.7 (19.5; 21.9)	77 [3.0]	479 [26.5]	429 [65.1]	985 [16.5]	15.1 (14.1; 16.0)
IV	64 [2.5]	462 [26.2]	328 [71.2]	854 [14.7]	15.5 (14.4; 16.5)	71 [2.8]	358 [19.8]	369 [56.0]	798 [13.4]	12.2 (11.4; 13.1)
X/NA	9 [0.3]	41 [2.3]	60 [13.0]	110 [1.9]	2.1 (1.7; 2.5)	5 [0.2]	24 [1.3]	60 [9.1]	89 [1.5]	1.3 (1.0; 1.5)

1.2.4. Colorectal cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Sub-locations	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-49	50-74	75+	All ages 0+		15-49	50-74	75+	All ages 0+	
Colon	I	37 [1.4]	406 [23.0]	293 [63.6]	738 [12.7]	13.3 (12.4; 14.3)	30 [1.2]	329 [18.2]	267 [40.5]	630 [10.6]	9.6 (8.9; 10.4)
	II	44 [1.7]	367 [20.8]	397 [86.2]	811 [14.0]	15.0 (14.0; 16.0)	61 [2.4]	321 [17.8]	433 [65.7]	816 [13.7]	12.1 (11.3; 13.0)
	III	44 [1.7]	367 [20.8]	279 [60.6]	690 [11.9]	12.6 (11.6; 13.5)	45 [1.8]	310 [17.1]	335 [50.8]	690 [11.6]	10.4 (9.6; 11.2)
	IV	44 [1.7]	322 [18.2]	243 [52.8]	609 [10.5]	11.1 (10.2; 12.0)	56 [2.2]	260 [14.4]	311 [47.2]	627 [10.5]	9.5 (8.8; 10.3)
	X/NA	4 [0.2]	30 [1.7]	38 [8.2]	72 [1.2]	1.4 (1.1; 1.7)	3 [0.1]	16 [0.9]	43 [6.5]	62 [1.0]	0.9 (0.7; 1.1)
Rectum	I	23 [0.9]	227 [12.9]	105 [22.8]	355 [6.1]	6.4 (5.7; 7.0)	27 [1.1]	121 [6.7]	55 [8.3]	203 [3.4]	3.2 (2.8; 3.7)
	II	9 [0.3]	99 [5.6]	84 [18.2]	192 [3.3]	3.5 (3.0; 4.0)	8 [0.3]	50 [2.8]	57 [8.6]	115 [1.9]	1.7 (1.4; 2.0)
	III	43 [1.7]	283 [16.0]	127 [27.6]	453 [7.8]	8.1 (7.3; 8.8)	32 [1.2]	169 [9.3]	94 [14.3]	295 [4.9]	4.7 (4.1; 5.2)
	IV	20 [0.8]	140 [7.9]	85 [18.5]	245 [4.2]	4.4 (3.9; 5.0)	15 [0.6]	98 [5.4]	58 [8.8]	171 [2.9]	2.7 (2.3; 3.1)
	X/NA	5 [0.2]	11 [0.6]	22 [4.8]	38 [0.7]	0.7 (0.5; 0.9)	2 [0.1]	8 [0.4]	17 [2.6]	27 [0.5]	0.4 (0.2; 0.5)

1.2.5. Rectal cancer incidence by stage variables, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage variables	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-49	50-74	75+	All ages 0+		15-49	50-74	75+	All ages 0+	
Clinical stage	I	17 [0.7]	179 [10.1]	92 [20.0]	288 [5.0]	5.2 (4.6; 5.8)	22 [0.9]	97 [5.4]	48 [7.3]	167 [2.8]	2.6 (2.2; 3.0)
	II	6 [0.2]	94 [5.3]	80 [17.4]	180 [3.1]	3.3 (2.8; 3.8)	8 [0.3]	48 [2.7]	54 [8.2]	110 [1.8]	1.6 (1.3; 2.0)
	III	46 [1.8]	276 [15.6]	129 [28.0]	451 [7.8]	8.0 (7.3; 8.8)	30 [1.2]	166 [9.2]	93 [14.1]	289 [4.8]	4.6 (4.0; 5.1)
	IV	20 [0.8]	138 [7.8]	84 [18.2]	242 [4.2]	4.4 (3.8; 4.9)	14 [0.5]	96 [5.3]	57 [8.6]	167 [2.8]	2.6 (2.2; 3.0)
	X/NA	11 [0.4]	73 [4.1]	38 [8.2]	122 [2.1]	2.2 (1.8; 2.6)	10 [0.4]	39 [2.2]	29 [4.4]	78 [1.3]	1.2 (0.9; 1.5)
Pathological stage without NAT	I	22 [0.8]	196 [11.1]	75 [16.3]	293 [5.1]	5.2 (4.6; 5.8)	23 [0.9]	110 [6.1]	43 [6.5]	176 [2.9]	2.8 (2.4; 3.2)
	II	5 [0.2]	36 [2.0]	38 [8.2]	79 [1.4]	1.4 (1.1; 1.8)	3 [0.1]	23 [1.3]	29 [4.4]	55 [0.9]	0.8 (0.6; 1.0)
	III	7 [0.3]	57 [3.2]	34 [7.4]	98 [1.7]	1.8 (1.4; 2.1)	4 [0.2]	30 [1.7]	34 [5.2]	68 [1.1]	1.0 (0.8; 1.3)
	IV	2 [0.1]	9 [0.5]	3 [0.7]	14 [0.2]	0.3 (0.1; 0.4)	2 [0.1]	12 [0.7]	4 [0.6]	18 [0.3]	0.3 (0.2; 0.4)
	X/NA	29 [1.1]	265 [15.0]	211 [45.8]	505 [8.7]	9.2 (8.4; 10.0)	24 [0.9]	156 [8.6]	128 [19.4]	308 [5.2]	4.7 (4.2; 5.2)
Pathological stage after NAT	I	7 [0.3]	57 [3.2]	21 [4.6]	85 [1.5]	1.5 (1.2; 1.8)	3 [0.1]	22 [1.2]	9 [1.4]	34 [0.6]	0.6 (0.4; 0.7)
	II	6 [0.2]	45 [2.5]	10 [2.2]	61 [1.1]	1.1 (0.8; 1.4)	3 [0.1]	33 [1.8]	14 [2.1]	50 [0.8]	0.8 (0.6; 1.0)
	III	9 [0.3]	45 [2.5]	16 [3.5]	70 [1.2]	1.2 (1.0; 1.5)	12 [0.5]	29 [1.6]	10 [1.5]	51 [0.9]	0.8 (0.6; 1.1)
	IV	3 [0.1]	5 [0.3]	6 [1.3]	14 [0.2]	0.3 (0.1; 0.4)	2 [0.1]	4 [0.2]	3 [0.5]	9 [0.2]	0.1 (0.0; 0.2)
	X/NA	10 [0.4]	45 [2.5]	9 [2.0]	64 [1.1]	1.1 (0.8; 1.4)	8 [0.3]	27 [1.5]	7 [1.1]	42 [0.7]	0.7 (0.5; 0.9)

2. CANCER INCIDENCE TRENDS



2.1. Colorectal cancer incidence trends: by region

2.1.1. Colorectal cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	
Belgium	N	4,108	4,155	4,261	4,250	4,518	4,537	4,592	4,800	4,752	4,804	5,608	4,933	4,767	4,591	4,315	4,327	3,984	4,392	4,265	4,310	4,203			
	CR	80.8	81.3	82.8	82.0	86.5	86.1	86.4	89.4	87.8	88.2	102.4	89.6	86.1	82.5	77.1	76.9	70.4	77.4	74.7	74.8	72.5			
	ESR2013	106.1	105.0	106.6	103.1	107.7	106.3	104.7	108.6	105.9	104.9	120.3	103.8	99.1	92.8	86.3	84.6	77.1	84.1	80.3	79.6	76.4	-1.6 (-2.0; -1.2)	2004-2024	
																							0.7 (-0.3; 1.7)	2004-2013	
																								-4.6 (-6.5; -2.6)	2014-2017
																								-2.7 (-4.1; -1.4)	2018-2024
Brussels	N	299	316	310	337	337	281	357	356	320	312	320	301	337	333	320	302	267	322	325	325	314			
	CR	62.2	65.3	63.3	67.8	66.7	54.4	67.8	65.6	57.9	55.5	56.5	52.6	58.1	57.2	54.5	51.0	44.7	53.7	54.1	53.4	51.3			
	ESR2013	94.5	96.5	95.2	102.8	101.8	84.1	103.5	103.7	93.0	88.2	90.0	84.0	91.9	91.6	86.0	81.1	70.6	83.1	84.7	81.0	76.3	-1.2 (-1.8; -0.7)	2004-2024	
Flanders	N	2,603	2,642	2,749	2,699	2,932	2,983	2,905	3,082	3,060	3,063	3,928	3,289	2,969	2,772	2,568	2,558	2,459	2,599	2,486	2,445	2,471			
	CR	87.7	88.7	91.7	89.5	96.5	97.4	94.2	99.0	97.6	97.2	124.1	103.3	92.8	86.1	79.2	78.5	75.0	78.9	75.0	72.9	73.2			
	ESR2013	110.8	110.2	112.6	106.9	113.8	113.6	107.8	113.6	110.1	107.9	136.1	111.3	98.9	90.2	82.5	80.2	76.3	79.9	75.0	72.4	71.9	-2.2 (-2.8; -1.6)	2004-2024	
																								1.0 (-0.5; 2.5)	2004-2013
																									-6.4 (-9.2; -3.6)
																								-3.7 (-5.6; -1.7)	2018-2024

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Wallonia N	1,206	1,197	1,202	1,214	1,249	1,273	1,330	1,362	1,372	1,429	1,360	1,343	1,461	1,486	1,427	1,467	1,258	1,471	1,454	1,540	1,418		
CR	73.5	72.6	72.6	72.8	74.4	75.4	78.2	79.4	79.5	82.4	78.1	76.8	83.2	84.2	80.6	82.6	70.6	82.4	81.1	85.5	78.5		
ESR2013	100.0	97.2	97.7	95.5	96.8	96.7	99.0	99.7	100.3	103.0	95.3	93.4	100.8	98.5	93.7	94.8	80.5	92.7	89.9	93.5	85.5	-0.6 (-0.9; -0.2)	2004-2024
																						0.1 (-0.6; 0.8)	2004-2014
																						-1.2 (-1.9; -0.5)	2015-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Colorectal cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	N	3,507	3,464	3,584	3,645	3,715	3,734	3,743	3,758	3,896	3,894	4,131	3,854	3,769	3,649	3,586	3,714	3,353	3,480	3,437	3,551	3,636		
	CR	66.1	64.9	66.8	67.5	68.3	68.1	67.7	67.3	69.3	68.9	72.8	67.6	65.8	63.4	62.1	64.0	57.5	59.5	58.5	59.8	60.9		
	ESR2013	66.2	65.0	66.2	66.0	66.8	66.0	65.4	65.0	66.5	66.0	70.4	63.9	62.2	59.3	57.1	58.8	52.7	54.5	53.2	54.9	55.3	-1.1 (-1.4; -0.8)	2004-2024
																							0.5 (-0.5; 1.4)	2004-2011
																							-1.9 (-2.4; -1.4)	2012-2024
Brussels	N	327	326	351	294	304	277	319	342	300	298	300	305	306	292	283	317	272	263	267	283	309		
	CR	62.9	62.3	66.3	55.0	56.1	50.2	56.7	59.3	51.2	50.3	50.3	50.6	50.3	47.9	46.2	51.5	43.8	42.4	42.9	44.7	48.5		
	ESR2013	65.1	64.3	70.9	58.6	60.3	54.7	62.3	67.6	58.2	58.6	59.2	60.4	61.1	57.0	54.8	61.5	52.6	50.7	51.4	56.1	59.7	-0.9 (-1.4; -0.4)	2004-2024
Flanders	N	2,052	2,003	2,144	2,216	2,296	2,335	2,344	2,225	2,399	2,412	2,699	2,378	2,301	2,190	2,134	2,200	2,015	2,085	1,986	2,066	2,022		
	CR	67.3	65.4	69.6	71.5	73.5	74.3	74.0	69.7	74.6	74.7	83.2	72.9	70.2	66.5	64.4	66.1	60.2	62.1	58.7	60.4	58.7		
	ESR2013	67.1	64.9	68.2	68.8	70.7	70.2	69.7	65.3	69.1	68.7	77.7	66.1	63.3	59.4	55.8	57.8	52.2	53.6	50.6	52.7	50.1	-1.6 (-2.1; -1.2)	2004-2024
																							0.7 (-0.8; 2.2)	2004-2011
																							-1.4 (-3.5; 0.8)	2012-2015
																							-3.5 (-4.5; -2.4)	2016-2024
Wallonia	N	1,128	1,135	1,089	1,135	1,115	1,122	1,080	1,191	1,197	1,184	1,132	1,171	1,162	1,167	1,169	1,197	1,066	1,132	1,184	1,202	1,305		
	CR	64.8	64.9	62.0	64.2	62.7	62.8	60.1	65.8	65.7	64.7	61.7	63.6	63.0	63.1	63.0	64.4	57.2	60.7	63.3	63.9	69.2		
	ESR2013	65.3	65.2	60.9	63.1	61.2	61.2	58.4	63.6	63.7	62.8	59.6	60.9	60.2	59.8	59.7	60.2	53.3	56.9	58.4	59.0	63.6	-0.4 (-0.7; -0.1)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Colorectal cancer incidence trends: by tumour stage

2.2.1. Colorectal cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

Stage		Males							Females						
		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
I	N	920	1,041	1,018	1,132	1,093			743	764	760	840	833		
	CR	16.3	18.3	17.8	19.6	18.9			12.7	13.1	12.9	14.2	14.0		
	ESR2013	17.6	19.8	19.0	20.7	19.7	1.6 (0.8; 2.4)	2004-2024	11.8	12.1	11.9	13.3	12.9	1.9 (1.3; 2.4)	2004-2024
							6.0 (4.1; 7.9)	2004-2014						5.0 (3.9; 6.1)	2004-2015
							-2.6 (-4.4; -0.9)	2015-2024						-1.9 (-3.1; -0.6)	2016-2024
II	N	948	1,058	999	994	1,003			887	919	915	929	931		
	CR	16.7	18.6	17.5	17.3	17.3			15.2	15.7	15.6	15.6	15.6		
	ESR2013	18.6	20.5	19.1	18.7	18.5	-2.3 (-2.6; -1.9)	2004-2024	13.7	14.1	13.9	14.1	13.9	-1.5 (-1.8; -1.2)	2004-2024
							-0.3 (-1.1; 0.5)	2004-2013						-0.2 (-1.0; 0.5)	2004-2013
							-5.7 (-7.2; -4.1)	2014-2017						-4.7 (-6.1; -3.2)	2014-2017
						-2.8 (-3.9; -1.8)	2018-2024						-1.2 (-2.3; -0.2)	2018-2024	
III	N	1,118	1,224	1,159	1,202	1,143			923	986	971	954	985		
	CR	19.8	21.6	20.3	20.9	19.7			15.8	16.9	16.5	16.1	16.5		
	ESR2013	21.5	23.2	21.5	22.0	20.7	-1.2 (-1.7; -0.7)	2004-2024	14.6	15.5	15.1	14.8	15.1	-0.9 (-1.2; -0.5)	2004-2024
							3.1 (1.5; 4.7)	2004-2011						1.7 (0.7; 2.6)	2004-2012
							-2.9 (-5.1; -0.7)	2012-2015						-3.6 (-5.2; -2.0)	2013-2016
						-3.7 (-4.8; -2.6)	2016-2024						-2.0 (-2.9; -1.0)	2017-2024	
IV	N	889	969	977	893	854			718	726	692	734	798		
	CR	15.7	17.1	17.1	15.5	14.7			12.3	12.4	11.8	12.4	13.4		
	ESR2013	17.2	18.6	18.4	16.5	15.5	-0.2 (-0.6; 0.2)	2004-2024	11.3	11.5	10.9	11.5	12.2	1.0 (0.5; 1.4)	2004-2024

Stage	Males							Females						
	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
						2.2 (1.0; 3.5)	2004-2011						4.9 (2.4; 7.5)	2004-2008
						-1.5 (-2.0; -0.9)	2012-2024						0.0 (-0.5; 0.5)	2009-2024
X/NA N	109	100	112	89	110			82	85	99	94	89		
CR	1.9	1.8	2.0	1.5	1.9			1.4	1.5	1.7	1.6	1.5		
ESR2013	2.2	2.0	2.3	1.7	2.1	-11.7 (-12.8; -10.7)	2004-2024	1.2	1.2	1.5	1.4	1.3	-11.0 (-12.0; -9.8)	2004-2024
						-9.1 (-12.1; -6.0)	2004-2012						-9.3 (-11.5; -7.0)	2004-2014
						-16.1 (-20.9; -11.1)	2013-2016						-18.8 (-23.4; -13.8)	2015-2018
						-12.1 (-15.0; -9.1)	2017-2024						-8.2 (-12.5; -3.7)	2019-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Colorectal cancer incidence trends: by age group

2.3.1. Colorectal cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-39 N	43	55	61	61	49	72	70	66	65	88	56	65	65	85	69	81	72	102	82	90	80		
CR	2.5	3.2	3.5	3.5	2.8	4.1	4.0	3.8	3.7	5.0	3.2	3.7	3.7	4.8	3.9	4.6	4.0	5.7	4.6	5.0	4.4		
ESR2013	2.4	3.2	3.5	3.6	2.9	4.2	4.1	3.9	3.8	5.1	3.3	3.8	3.8	4.9	4.0	4.7	4.2	5.8	4.7	5.1	4.6	2.5 (1.4; 3.6)	2004-2024
40-49 N	194	160	179	176	200	146	175	169	176	187	189	159	170	164	130	174	161	165	174	164	193		
CR	24.6	20.0	22.2	21.6	24.5	17.9	21.5	20.7	21.6	23.1	23.6	20.1	21.8	21.3	17.0	22.9	21.2	21.8	23.0	21.6	25.4		
ESR2013	24.8	20.1	22.3	21.8	24.6	17.9	21.4	20.5	21.4	22.8	23.4	20.0	21.6	21.1	16.8	22.6	21.0	21.8	23.1	21.7	25.5	0.5 (-0.3; 1.3)	2004-2024
																						-0.5 (-1.5; 0.4)	2004-2020
																						4.7 (0.0; 9.5)	2021-2024
50-74 N	2,358	2,391	2,367	2,328	2,491	2,564	2,556	2,683	2,610	2,602	3,520	2,825	2,708	2,617	2,448	2,431	2,157	2,430	2,330	2,398	2,252		
CR	174.9	175.1	171.3	166.3	175.4	177.5	174.0	179.3	171.5	168.4	224.2	176.9	166.6	158.1	145.7	143.0	125.5	140.0	133.5	136.5	127.6		
ESR2013	182.6	182.8	180.6	176.3	187.0	190.5	186.0	192.2	184.9	182.4	243.8	187.7	179.2	166.0	152.1	147.8	129.2	142.9	135.9	138.8	129.0	-1.6 (-2.3; -0.9)	2004-2024
																						1.5 (-0.2; 3.2)	2004-2013
																						-5.0 (-8.2; -1.7)	2014-2017
																						-3.6 (-5.8; -1.4)	2018-2024
75+ N	1,509	1,545	1,651	1,682	1,777	1,752	1,786	1,880	1,898	1,923	1,838	1,882	1,815	1,718	1,666	1,639	1,592	1,687	1,673	1,653	1,673		
CR	514.8	510.4	525.7	516.3	527.7	507.0	504.5	520.5	514.2	511.3	479.3	480.7	459.8	435.2	419.4	405.6	385.0	405.5	388.0	371.2	363.2		
ESR2013	522.1	514.7	534.9	510.6	524.7	503.3	495.4	520.0	513.6	502.8	475.7	482.6	455.0	427.2	411.3	395.8	379.1	402.5	386.1	369.7	362.8	-1.9 (-2.1; -1.7)	2004-2024
																						-0.4 (-1.0; 0.2)	2004-2012
																						-2.9 (-3.3; -2.6)	2013-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.2. Colorectal cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-39 N	49	56	67	68	79	66	73	70	90	92	79	89	92	91	92	89	85	94	86	108	104		
CR	2.9	3.3	4.0	4.0	4.7	3.9	4.3	4.1	5.2	5.3	4.6	5.1	5.3	5.2	5.3	5.1	4.8	5.4	4.9	6.0	5.8		
ESR2013	2.9	3.3	4.0	4.0	4.7	3.9	4.3	4.1	5.3	5.5	4.7	5.2	5.4	5.3	5.3	5.1	4.9	5.4	4.9	6.0	5.8	2.6 (2.0; 3.3)	2004-2024
																						5.2 (3.5; 6.9)	2004-2013
																						0.6 (-0.6; 2.0)	2014-2024
40-49 N	126	162	170	169	142	153	149	153	169	153	154	158	157	135	127	133	135	153	162	177	175		
CR	16.2	20.6	21.4	21.2	17.8	19.2	18.7	19.2	21.3	19.4	19.7	20.5	20.7	18.0	17.0	17.8	18.1	20.5	21.7	23.5	23.1		
ESR2013	16.3	20.7	21.6	21.3	17.8	19.2	18.6	19.0	21.2	19.3	19.6	20.4	20.6	17.7	16.8	17.7	18.0	20.5	21.8	23.6	23.2	1.1 (0.4; 1.8)	2004-2024
																						-0.4 (-1.1; 0.4)	2004-2020
																						7.0 (2.9; 11.2)	2021-2024
50-74 N	1,634	1,626	1,641	1,583	1,686	1,655	1,684	1,665	1,725	1,770	2,066	1,789	1,754	1,752	1,637	1,729	1,532	1,644	1,511	1,677	1,682		
CR	113.4	111.8	111.9	106.9	112.7	109.2	109.4	106.4	108.6	109.9	126.7	108.1	104.4	102.5	94.5	98.8	86.7	92.2	84.4	93.0	93.1		
ESR2013	112.4	111.3	112.6	108.6	115.2	111.6	112.7	110.2	112.4	114.0	132.1	111.4	108.3	104.7	95.7	99.4	86.8	91.8	83.9	92.4	92.3	-1.2 (-1.7; -0.7)	2004-2024
																						0.8 (-0.4; 2.0)	2004-2013
																						-3.5 (-5.9; -1.1)	2014-2017
																						-2.3 (-3.9; -0.6)	2018-2024
75+ N	1,697	1,615	1,703	1,819	1,803	1,856	1,828	1,864	1,910	1,874	1,825	1,815	1,763	1,670	1,726	1,758	1,593	1,585	1,673	1,586	1,670		
CR	326.4	304.1	312.8	326.3	316.5	320.9	311.6	314.2	318.3	310.1	299.1	294.1	286.0	272.7	282.4	286.2	256.7	256.1	263.9	245.7	253.4		
ESR2013	325.7	306.7	311.8	323.1	312.8	316.5	305.5	309.6	312.9	303.6	294.4	288.2	278.6	264.0	270.5	276.3	249.3	247.8	259.6	244.1	249.6	-1.3 (-1.5; -1.1)	2004-2024
																						-0.3 (-0.9; 0.4)	2004-2012
																						-2.9 (-4.0; -1.8)	2013-2016
																						-1.5 (-2.1; -0.9)	2017-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Colorectal cancer prevalence: by region

3.1.1. Colorectal cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	N	3,638	14,520	24,919	32,711	36,903	3,169	12,384	21,241	27,815	31,939
	CR	62.4	249.1	427.4	561	633	52.9	206.6	354.3	464	533
	ESR2013	64.8	259.3	447.0	590.1	668.2	47.9	185.7	315.4	409.9	467.8
Brussels	N	274	1,038	1,675	2,119	2,365	273	969	1,611	2,077	2,362
	CR	44.5	168.7	272.2	344.4	384.3	42.6	151.3	251.5	324.3	368.8
	ESR2013	64.9	253.4	419.1	539.2	608.5	52.3	184.6	304.8	391.8	444.4
Flanders	N	2,147	8,644	15,402	20,805	23,679	1,787	7,338	12,922	17,246	19,888
	CR	63.2	254.2	453.0	611.9	696.5	51.6	211.8	372.9	497.7	574.0
	ESR2013	61.3	247.1	440.4	596.4	679.9	44.1	180.6	315.0	416.6	476.9
Wallonia	N	1,217	4,838	7,842	9,787	10,859	1,109	4,077	6,708	8,492	9,689
	CR	67.1	266.6	432.1	539.3	598.3	58.7	215.7	354.9	449.3	512.6
	ESR2013	72.0	285.2	466.2	585.8	654.4	53.8	195.3	318.1	400.6	455.1

4. CANCER SURVIVAL



4.1. Colorectal cancer survival: by region

4.1.1. Colorectal cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024

Net Survival Probability, 2015-2024						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All ages 15+	77,541	85.8% (85.6%; 86.1%)	75.4% (75.0%; 75.8%)	70.6% (70.0%; 71.1%)	65.4% (63.1%; 67.7%)
Males						
Belgium	All ages 15+	42,569	86.4% (86.0%; 86.8%)	75.5% (75.0%; 76.1%)	69.9% (69.2%; 70.6%)	63.3% (59.9%; 67.0%)
	15-49	2,380	94.9% (94.0%; 95.8%)	82.9% (81.3%; 84.5%)	75.7% (73.8%; 77.7%)	69.7% (67.3%; 72.3%)
	50-74	23,886	90.4% (90.0%; 90.8%)	79.7% (79.1%; 80.3%)	73.5% (72.8%; 74.2%)	67.2% (66.1%; 68.3%)
	75+	16,339	79.4% (78.6%; 80.1%)	68.3% (67.2%; 69.4%)	63.8% (62.3%; 65.3%)	56.8% (48.7%; 66.4%)
Brussels	All ages 15+	3,034	84.1% (82.6%; 85.6%)	71.9% (69.8%; 74.0%)	66.3% (63.7%; 69.1%)	55.5% (47.2%; 65.1%)
	15-49	291	91.8% (88.7%; 95.1%)	77.9% (73.0%; 83.1%)	68.7% (62.8%; 75.1%)	62.2% (54.5%; 71.1%)
	50-74	1,687	87.0% (85.3%; 88.7%)	75.8% (73.5%; 78.2%)	69.2% (66.4%; 72.1%)	62.8% (58.5%; 67.4%)
	75+	1,057	77.2% (74.2%; 80.4%)	63.9% (59.7%; 68.4%)	60.9% (55.3%; 67.1%)	43.6% (28.8%; 66.0%)
Flanders	All ages 15+	25,701	87.5% (87.0%; 88.0%)	77.2% (76.6%; 77.9%)	72.0% (71.1%; 72.9%)	65.7% (60.7%; 71.0%)
	15-49	1,315	96.2% (95.1%; 97.2%)	84.9% (82.9%; 87.0%)	78.0% (75.5%; 80.5%)	71.8% (68.6%; 75.0%)
	50-74	13,934	91.6% (91.1%; 92.1%)	82.3% (81.5%; 83.0%)	76.3% (75.4%; 77.2%)	70.6% (69.3%; 72.1%)
	75+	10,474	80.9% (79.9%; 81.8%)	69.6% (68.3%; 71.0%)	65.4% (63.6%; 67.3%)	58.3% (47.1%; 72.1%)
Wallonia	All ages 15+	13,835	84.9% (84.2%; 85.6%)	73.1% (72.1%; 74.1%)	66.8% (65.5%; 68.1%)	60.5% (57.1%; 64.1%)

Net Survival Probability, 2015-2024						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	15-49	774	93.9% (92.2%; 95.6%)	81.4% (78.6%; 84.3%)	74.5% (71.2%; 78.0%)	68.9% (64.8%; 73.3%)
	50-74	8,266	88.9% (88.2%; 89.6%)	76.3% (75.2%; 77.4%)	69.6% (68.4%; 70.9%)	61.9% (59.8%; 64.2%)
	75+	4,808	76.6% (75.1%; 78.0%)	66.3% (64.3%; 68.4%)	60.6% (57.8%; 63.6%)	56.8% (48.5%; 66.5%)
Females						
Belgium	All ages 15+	34,972	85.2% (84.8%; 85.6%)	75.3% (74.7%; 75.9%)	71.4% (70.6%; 72.2%)	67.9% (65.6%; 70.4%)
	15-49	2,406	95.0% (94.1%; 95.9%)	84.6% (83.1%; 86.1%)	79.3% (77.6%; 81.1%)	75.9% (73.7%; 78.1%)
	50-74	16,296	90.5% (90.0%; 91.0%)	80.5% (79.8%; 81.2%)	75.5% (74.7%; 76.3%)	70.8% (69.6%; 72.0%)
	75+	16,301	78.4% (77.7%; 79.1%)	68.7% (67.7%; 69.8%)	66.1% (64.7%; 67.5%)	63.9% (59.0%; 69.1%)
Brussels	All ages 15+	2,797	83.5% (82.0%; 85.0%)	73.7% (71.6%; 75.8%)	68.9% (66.1%; 71.7%)	58.3% (48.7%; 69.9%)
	15-49	267	95.5% (93.1%; 98.1%)	83.0% (78.4%; 87.9%)	79.3% (74.1%; 84.8%)	76.1% (69.6%; 83.2%)
	50-74	1,299	89.7% (88.0%; 91.5%)	79.4% (77.0%; 81.9%)	72.0% (69.1%; 75.0%)	65.3% (60.7%; 70.1%)
	75+	1,232	74.3% (71.5%; 77.2%)	65.7% (62.0%; 69.6%)	63.1% (58.1%; 68.6%)	49.6% (34.6%; 71.2%)
Flanders	All ages 15+	20,740	86.5% (85.9%; 87.0%)	76.9% (76.2%; 77.7%)	73.5% (72.5%; 74.5%)	69.3% (66.5%; 72.2%)
	15-49	1,392	95.3% (94.2%; 96.5%)	85.8% (84.0%; 87.7%)	80.7% (78.5%; 83.0%)	77.5% (74.9%; 80.3%)
	50-74	9,295	91.8% (91.2%; 92.4%)	82.4% (81.6%; 83.3%)	78.3% (77.3%; 79.3%)	73.4% (71.9%; 75.0%)
	75+	10,073	80.3% (79.4%; 81.2%)	70.7% (69.4%; 72.0%)	68.1% (66.3%; 69.9%)	64.4% (58.8%; 70.5%)
Wallonia	All ages 15+	11,435	83.2% (82.5%; 84.0%)	72.8% (71.7%; 73.8%)	68.2% (66.8%; 69.6%)	68.1% (63.7%; 72.9%)
	15-49	747	94.1% (92.4%; 95.8%)	82.9% (80.1%; 85.7%)	76.7% (73.4%; 80.1%)	72.5% (68.6%; 76.7%)
	50-74	5,702	88.6% (87.7%; 89.5%)	77.6% (76.4%; 78.8%)	71.7% (70.3%; 73.1%)	67.7% (65.6%; 69.9%)
	75+	4,996	75.5% (74.1%; 76.9%)	65.6% (63.8%; 67.6%)	62.8% (60.2%; 65.5%)	67.1% (57.6%; 78.2%)

4.2. Colorectal cancer survival: by sub-location and tumour stage

4.2.1. Colorectal cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024

location	cStage	Net Survival Probability, 2015-2024						
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total		77,541	85.8% (85.6%; 86.1%)	79.6% (79.3%; 80.0%)	75.4% (75.0%; 75.8%)	72.4% (71.9%; 72.8%)	70.6% (70.0%; 71.1%)	65.4% (63.1%; 67.7%)
Males								
CRC	All	42,569	86.4% (86.0%; 86.8%)	80.1% (79.6%; 80.5%)	75.5% (75.0%; 76.1%)	72.0% (71.4%; 72.6%)	69.9% (69.2%; 70.6%)	63.3% (59.9%; 67.0%)
	I	7,187	96.1% (95.4%; 96.7%)	94.7% (93.8%; 95.6%)	93.3% (92.1%; 94.4%)	91.3% (89.9%; 92.7%)	90.2% (88.5%; 91.8%)	90.7% (86.2%; 95.5%)
	II	6,473	91.6% (90.8%; 92.5%)	87.9% (86.7%; 89.0%)	84.4% (83.0%; 85.8%)	81.3% (79.6%; 83.0%)	79.7% (77.7%; 81.8%)	64.4% (45.3%; 91.4%)
	III	9,098	93.4% (92.7%; 94.0%)	88.7% (87.8%; 89.6%)	85.0% (84.0%; 86.1%)	81.2% (80.0%; 82.5%)	79.1% (77.7%; 80.6%)	73.4% (69.5%; 77.5%)
	IV	8,222	61.8% (60.7%; 62.9%)	42.6% (41.4%; 43.7%)	30.3% (29.2%; 31.4%)	22.8% (21.7%; 23.9%)	18.5% (17.4%; 19.6%)	10.7% (9.4%; 12.3%)
	X/NA	12,305	89.2% (88.5%; 89.9%)	85.9% (85.1%; 86.7%)	83.4% (82.4%; 84.3%)	81.3% (80.2%; 82.4%)	79.7% (78.4%; 81.0%)	73.8% (70.6%; 77.2%)
Colon	All	29,526	85.6% (85.2%; 86.1%)	79.4% (78.8%; 80.0%)	75.1% (74.4%; 75.7%)	71.8% (71.1%; 72.6%)	69.9% (69.0%; 70.8%)	63.4% (58.6%; 68.6%)
	I	4,694	96.3% (95.4%; 97.1%)	95.1% (94.0%; 96.2%)	93.7% (92.3%; 95.1%)	91.6% (89.8%; 93.4%)	90.1% (88.0%; 92.2%)	82.9% (77.2%; 89.0%)
	II	4,577	92.2% (91.2%; 93.3%)	89.1% (87.8%; 90.5%)	85.9% (84.3%; 87.6%)	83.9% (81.9%; 86.0%)	82.7% (80.2%; 85.2%)	66.6% (40.2%; 110.4%)
	III	4,268	91.7% (90.7%; 92.7%)	86.8% (85.4%; 88.1%)	83.0% (81.4%; 84.6%)	79.2% (77.3%; 81.2%)	77.5% (75.2%; 79.8%)	77.8% (70.8%; 85.4%)
	IV	5,811	59.4% (58.1%; 60.7%)	40.3% (39.0%; 41.7%)	28.6% (27.4%; 30.0%)	21.5% (20.3%; 22.8%)	17.5% (16.3%; 18.8%)	10.5% (8.7%; 12.6%)
	X/NA	10,553	89.9% (89.2%; 90.6%)	86.6% (85.7%; 87.5%)	84.2% (83.2%; 85.2%)	82.1% (80.9%; 83.3%)	80.6% (79.2%; 82.0%)	74.8% (71.2%; 78.6%)
Rectum	All	13,586	88.0% (87.4%; 88.7%)	81.4% (80.6%; 82.2%)	76.3% (75.3%; 77.2%)	72.0% (71.0%; 73.1%)	69.6% (68.4%; 70.8%)	63.0% (60.2%; 65.9%)
	I	2,529	95.6% (94.5%; 96.7%)	93.8% (92.3%; 95.3%)	92.1% (90.3%; 94.0%)	90.3% (88.2%; 92.6%)	89.8% (87.2%; 92.4%)	100.3% (93.2%; 108.0%)
	II	1,915	90.2% (88.6%; 91.9%)	85.0% (82.9%; 87.1%)	80.9% (78.4%; 83.5%)	75.2% (72.2%; 78.4%)	73.1% (69.8%; 76.6%)	59.7% (51.4%; 69.4%)
	III	4,869	94.7% (93.9%; 95.5%)	90.3% (89.1%; 91.4%)	86.7% (85.3%; 88.1%)	82.8% (81.2%; 84.5%)	80.4% (78.6%; 82.3%)	70.8% (66.2%; 75.8%)
	IV	2,447	67.6% (65.6%; 69.6%)	47.9% (45.9%; 50.1%)	34.1% (32.1%; 36.3%)	25.8% (23.8%; 27.9%)	20.8% (18.9%; 22.9%)	11.6% (9.5%; 14.1%)
	X/NA	1,837	85.1% (83.2%; 86.9%)	81.7% (79.6%; 84.0%)	78.5% (76.0%; 81.1%)	76.8% (73.9%; 79.8%)	74.7% (71.4%; 78.1%)	67.0% (60.1%; 74.7%)

Net Survival Probability, 2015-2024									
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Females									
CRC	All	34,972	85.2% (84.8%; 85.6%)	79.0% (78.5%; 79.6%)	75.3% (74.7%; 75.9%)	72.9% (72.2%; 73.5%)	71.4% (70.6%; 72.2%)	67.9% (65.6%; 70.4%)	
	I	5,413	96.6% (95.9%; 97.3%)	95.8% (94.8%; 96.7%)	95.3% (94.1%; 96.5%)	94.6% (93.2%; 96.1%)	93.3% (91.5%; 95.2%)	81.7% (72.0%; 92.7%)	
	II	5,534	90.9% (90.0%; 91.9%)	87.8% (86.6%; 89.0%)	84.5% (83.0%; 86.0%)	82.2% (80.4%; 84.0%)	81.3% (79.2%; 83.5%)	76.4% (67.5%; 86.5%)	
	III	7,356	91.5% (90.8%; 92.3%)	87.4% (86.4%; 88.4%)	84.3% (83.1%; 85.5%)	82.0% (80.6%; 83.4%)	82.1% (80.5%; 83.7%)	83.0% (79.0%; 87.3%)	
	IV	6,452	56.8% (55.6%; 58.1%)	37.6% (36.4%; 38.9%)	27.4% (26.2%; 28.6%)	21.5% (20.4%; 22.7%)	18.0% (16.9%; 19.1%)	12.6% (11.0%; 14.6%)	
	X/NA	10,715	89.2% (88.5%; 89.9%)	85.4% (84.5%; 86.2%)	83.2% (82.2%; 84.2%)	81.6% (80.4%; 82.8%)	80.0% (78.7%; 81.4%)	77.5% (73.8%; 81.4%)	
Colon	All	26,778	84.6% (84.1%; 85.1%)	78.6% (78.0%; 79.2%)	75.2% (74.5%; 75.9%)	73.0% (72.2%; 73.8%)	71.7% (70.8%; 72.6%)	69.3% (66.5%; 72.4%)	
	I	3,931	96.2% (95.4%; 97.1%)	95.6% (94.5%; 96.7%)	95.2% (93.8%; 96.7%)	94.9% (93.1%; 96.7%)	93.4% (91.2%; 95.7%)	80.0% (66.9%; 95.6%)	
	II	4,356	91.1% (90.0%; 92.1%)	88.4% (87.0%; 89.7%)	85.4% (83.7%; 87.1%)	83.4% (81.4%; 85.4%)	82.9% (80.5%; 85.4%)	84.4% (73.6%; 96.7%)	
	III	4,275	90.2% (89.1%; 91.3%)	86.4% (85.1%; 87.8%)	83.8% (82.1%; 85.4%)	82.6% (80.7%; 84.5%)	83.6% (81.4%; 86.0%)	91.1% (85.0%; 97.7%)	
	IV	5,041	55.5% (54.1%; 57.0%)	36.0% (34.6%; 37.4%)	26.3% (25.0%; 27.6%)	20.6% (19.4%; 22.0%)	17.6% (16.3%; 18.9%)	13.2% (11.2%; 15.7%)	
	X/NA	9,508	89.8% (89.0%; 90.5%)	86.1% (85.2%; 87.0%)	84.3% (83.2%; 85.4%)	82.7% (81.4%; 84.0%)	81.1% (79.7%; 82.6%)	78.4% (74.3%; 82.8%)	
Rectum	All	8,452	87.1% (86.3%; 87.9%)	80.5% (79.5%; 81.5%)	75.7% (74.6%; 76.9%)	72.3% (71.0%; 73.6%)	70.3% (68.9%; 71.8%)	63.3% (59.9%; 66.9%)	
	I	1,495	97.4% (96.2%; 98.6%)	96.3% (94.6%; 98.0%)	95.2% (93.1%; 97.4%)	94.0% (91.4%; 96.7%)	93.0% (89.9%; 96.3%)	85.4% (76.3%; 95.7%)	
	II	1,189	90.4% (88.4%; 92.5%)	85.8% (83.2%; 88.5%)	81.1% (77.9%; 84.4%)	78.0% (74.4%; 81.9%)	75.9% (71.7%; 80.4%)	54.7% (41.4%; 72.2%)	
	III	3,098	93.4% (92.3%; 94.5%)	88.6% (87.2%; 90.0%)	85.1% (83.4%; 86.8%)	81.3% (79.4%; 83.3%)	80.2% (78.0%; 82.4%)	75.5% (70.5%; 80.9%)	
	IV	1,422	61.3% (58.8%; 64.0%)	43.3% (40.7%; 46.1%)	31.4% (28.9%; 34.1%)	24.7% (22.3%; 27.4%)	19.5% (17.2%; 22.1%)	11.0% (8.5%; 14.2%)	
	X/NA	1,251	85.2% (82.9%; 87.5%)	78.9% (76.2%; 81.7%)	74.3% (71.2%; 77.5%)	72.2% (68.8%; 75.8%)	71.1% (67.3%; 75.0%)	69.1% (62.8%; 76.0%)	

4.2.2. Colorectal cancer survival by sub-location, pathological stage ((y)pStage) and sex: number at risk and net survival probabilities, 2015-2024

Net Survival Probability, 2015-2024								
location	(y)pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total		77,541	85.8% (85.6%; 86.1%)	79.6% (79.3%; 80.0%)	75.4% (75.0%; 75.8%)	72.4% (71.9%; 72.8%)	70.6% (70.0%; 71.1%)	65.4% (63.1%; 67.7%)
Males								
CRC	All	42,569	86.4% (86.0%; 86.8%)	80.1% (79.6%; 80.5%)	75.5% (75.0%; 76.1%)	72.0% (71.4%; 72.6%)	69.9% (69.2%; 70.6%)	63.3% (59.9%; 67.0%)
	I	11,136	97.9% (97.5%; 98.4%)	97.4% (96.8%; 98.0%)	97.1% (96.3%; 97.9%)	96.0% (95.1%; 97.0%)	95.6% (94.4%; 96.8%)	91.5% (87.8%; 95.4%)
	II	10,443	95.5% (94.9%; 96.0%)	93.8% (93.0%; 94.6%)	92.0% (91.0%; 93.0%)	89.8% (88.5%; 91.0%)	88.7% (87.2%; 90.3%)	76.6% (65.3%; 89.8%)
	III	10,351	90.6% (90.0%; 91.3%)	83.3% (82.4%; 84.2%)	77.1% (76.0%; 78.2%)	71.8% (70.5%; 73.1%)	67.8% (66.4%; 69.3%)	62.5% (59.2%; 66.1%)
	IV	2,787	72.4% (70.7%; 74.2%)	54.3% (52.3%; 56.3%)	42.0% (40.0%; 44.1%)	34.4% (32.3%; 36.5%)	28.4% (26.4%; 30.6%)	16.8% (13.7%; 20.6%)
	X/NA	8,624	60.0% (58.9%; 61.1%)	45.4% (44.2%; 46.5%)	36.3% (35.1%; 37.6%)	31.3% (30.1%; 32.6%)	29.1% (27.9%; 30.5%)	25.4% (23.2%; 27.7%)
Colon	All	29,526	85.6% (85.2%; 86.1%)	79.4% (78.8%; 80.0%)	75.1% (74.4%; 75.7%)	71.8% (71.1%; 72.6%)	69.9% (69.0%; 70.8%)	63.4% (58.6%; 68.6%)
	I	7,205	97.5% (96.9%; 98.0%)	97.1% (96.3%; 97.9%)	96.5% (95.5%; 97.5%)	95.4% (94.1%; 96.7%)	95.0% (93.5%; 96.6%)	89.3% (84.8%; 94.1%)
	II	8,390	95.2% (94.5%; 95.8%)	93.7% (92.8%; 94.6%)	92.2% (91.0%; 93.3%)	90.6% (89.2%; 92.0%)	90.1% (88.4%; 91.9%)	78.1% (64.4%; 94.7%)
	III	7,906	89.5% (88.7%; 90.3%)	81.8% (80.7%; 82.9%)	75.7% (74.4%; 77.0%)	71.0% (69.5%; 72.4%)	67.1% (65.5%; 68.8%)	63.9% (59.8%; 68.3%)
	IV	2,324	70.1% (68.1%; 72.1%)	52.0% (49.8%; 54.3%)	39.7% (37.6%; 42.1%)	32.2% (30.0%; 34.5%)	26.8% (24.6%; 29.2%)	16.6% (13.1%; 21.1%)
	X/NA	4,164	47.1% (45.6%; 48.8%)	30.4% (28.9%; 32.0%)	21.8% (20.3%; 23.3%)	16.8% (15.4%; 18.3%)	14.6% (13.2%; 16.1%)	11.7% (9.7%; 14.0%)
Rectum	All	13,586	88.0% (87.4%; 88.7%)	81.4% (80.6%; 82.2%)	76.3% (75.3%; 77.2%)	72.0% (71.0%; 73.1%)	69.6% (68.4%; 70.8%)	63.0% (60.2%; 65.9%)
	I	4,019	98.6% (98.0%; 99.3%)	97.9% (97.0%; 98.9%)	98.0% (96.9%; 99.2%)	97.0% (95.5%; 98.6%)	96.4% (94.5%; 98.3%)	95.3% (89.0%; 102.1%)
	II	2,081	96.7% (95.6%; 97.9%)	94.4% (92.9%; 96.1%)	91.3% (89.3%; 93.4%)	86.7% (84.2%; 89.3%)	83.7% (80.7%; 86.7%)	71.3% (64.0%; 79.4%)
	III	2,485	94.1% (92.9%; 95.3%)	87.7% (86.1%; 89.4%)	81.2% (79.2%; 83.3%)	74.1% (71.7%; 76.6%)	69.8% (67.1%; 72.6%)	58.1% (53.2%; 63.5%)
	IV	476	83.6% (80.1%; 87.3%)	65.3% (60.7%; 70.2%)	52.0% (47.2%; 57.3%)	44.2% (39.3%; 49.7%)	35.9% (31.0%; 41.5%)	17.2% (12.0%; 24.8%)
	X/NA	4,535	71.8% (70.4%; 73.3%)	59.0% (57.4%; 60.6%)	49.6% (47.8%; 51.4%)	44.6% (42.7%; 46.5%)	42.4% (40.5%; 44.5%)	37.9% (34.2%; 42.0%)
Females								
CRC	All	34,972	85.2% (84.8%; 85.6%)	79.0% (78.5%; 79.6%)	75.3% (74.7%; 75.9%)	72.9% (72.2%; 73.5%)	71.4% (70.6%; 72.2%)	67.9% (65.6%; 70.4%)

Net Survival Probability, 2015-2024								
location	(y)pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	I	8,186	99.0% (98.5%; 99.4%)	98.8% (98.1%; 99.4%)	98.7% (97.9%; 99.6%)	98.7% (97.6%; 99.7%)	98.3% (97.0%; 99.7%)	99.1% (94.4%; 104.1%)
	II	9,260	95.7% (95.1%; 96.3%)	95.1% (94.3%; 95.9%)	94.1% (93.1%; 95.1%)	92.9% (91.6%; 94.1%)	92.0% (90.4%; 93.6%)	85.9% (80.5%; 91.7%)
	III	8,746	89.5% (88.7%; 90.2%)	82.1% (81.2%; 83.1%)	77.0% (75.9%; 78.2%)	73.3% (71.9%; 74.6%)	71.1% (69.6%; 72.6%)	66.8% (61.5%; 72.6%)
	IV	2,628	68.7% (66.8%; 70.6%)	50.5% (48.5%; 52.5%)	40.2% (38.2%; 42.3%)	32.8% (30.8%; 34.9%)	28.3% (26.3%; 30.4%)	19.3% (16.9%; 22.1%)
	X/NA	6,711	54.8% (53.6%; 56.1%)	39.9% (38.7%; 41.3%)	32.3% (31.1%; 33.7%)	28.7% (27.4%; 30.1%)	27.0% (25.6%; 28.5%)	24.6% (22.5%; 26.9%)
Colon	All	26,778	84.6% (84.1%; 85.1%)	78.6% (78.0%; 79.2%)	75.2% (74.5%; 75.9%)	73.0% (72.2%; 73.8%)	71.7% (70.8%; 72.6%)	69.3% (66.5%; 72.4%)
	I	5,858	98.7% (98.1%; 99.2%)	98.6% (97.8%; 99.4%)	98.6% (97.6%; 99.6%)	98.5% (97.2%; 99.8%)	97.9% (96.3%; 99.6%)	99.9% (94.1%; 106.1%)
	II	8,002	95.6% (94.9%; 96.2%)	95.1% (94.2%; 96.0%)	94.3% (93.2%; 95.4%)	93.7% (92.3%; 95.1%)	93.0% (91.3%; 94.8%)	88.5% (82.3%; 95.1%)
	III	7,211	88.4% (87.5%; 89.3%)	80.6% (79.5%; 81.8%)	75.8% (74.5%; 77.2%)	72.6% (71.1%; 74.1%)	71.0% (69.3%; 72.8%)	68.6% (62.3%; 75.6%)
	IV	2,300	67.5% (65.6%; 69.6%)	48.6% (46.5%; 50.9%)	38.8% (36.7%; 41.0%)	31.6% (29.5%; 33.9%)	27.3% (25.2%; 29.5%)	19.0% (16.4%; 22.0%)
	X/NA	3,811	43.1% (41.5%; 44.8%)	27.3% (25.8%; 29.0%)	19.9% (18.4%; 21.4%)	16.1% (14.6%; 17.6%)	14.6% (13.1%; 16.3%)	13.3% (11.3%; 15.6%)
Rectum	All	8,452	87.1% (86.3%; 87.9%)	80.5% (79.5%; 81.5%)	75.7% (74.6%; 76.9%)	72.3% (71.0%; 73.6%)	70.3% (68.9%; 71.8%)	63.3% (59.9%; 66.9%)
	I	2,369	99.7% (99.0%; 100.4%)	99.4% (98.3%; 100.4%)	99.0% (97.6%; 100.4%)	99.0% (97.3%; 100.8%)	99.3% (97.2%; 101.4%)	98.0% (90.3%; 106.3%)
	II	1,273	96.7% (95.3%; 98.1%)	95.4% (93.5%; 97.3%)	93.2% (90.8%; 95.7%)	87.7% (84.7%; 90.9%)	85.8% (82.2%; 89.4%)	70.0% (60.5%; 80.8%)
	III	1,549	94.3% (92.9%; 95.8%)	88.9% (87.0%; 90.9%)	82.2% (79.8%; 84.7%)	76.1% (73.2%; 79.0%)	71.4% (68.2%; 74.9%)	58.6% (51.4%; 66.7%)
	IV	332	77.0% (72.5%; 81.9%)	63.3% (58.1%; 69.0%)	50.1% (44.7%; 56.3%)	41.3% (35.8%; 47.6%)	36.1% (30.6%; 42.6%)	22.0% (16.2%; 30.0%)
	X/NA	2,932	70.0% (68.2%; 71.8%)	56.3% (54.3%; 58.3%)	48.5% (46.4%; 50.7%)	45.3% (43.0%; 47.6%)	43.3% (40.9%; 45.9%)	39.4% (35.6%; 43.7%)

4.2.3. Colorectal cancer survival by sub-location, stage and sex: number at risk and net survival probabilities, 2015-2024

Net Survival Probability, 2015-2024									
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Total		77,541	85.8% (85.6%; 86.1%)	79.6% (79.3%; 80.0%)	75.4% (75.0%; 75.8%)	72.4% (71.9%; 72.8%)	70.6% (70.0%; 71.1%)	65.4% (63.1%; 67.7%)	
Males									
CRC	All	42,569	86.4% (86.0%; 86.8%)	80.1% (79.6%; 80.5%)	75.5% (75.0%; 76.1%)	72.0% (71.4%; 72.6%)	69.9% (69.2%; 70.6%)	63.3% (59.9%; 67.0%)	
	I	10,658	96.5% (96.0%; 97.0%)	95.6% (94.9%; 96.3%)	94.6% (93.7%; 95.5%)	93.5% (92.4%; 94.5%)	92.9% (91.6%; 94.2%)	90.5% (86.7%; 94.5%)	
	II	10,340	93.5% (92.8%; 94.1%)	91.8% (91.0%; 92.6%)	89.9% (88.9%; 90.9%)	87.8% (86.5%; 89.1%)	86.9% (85.4%; 88.5%)	75.0% (63.7%; 88.3%)	
	III	12,074	92.6% (92.0%; 93.2%)	87.1% (86.3%; 87.9%)	82.8% (81.9%; 83.8%)	78.8% (77.6%; 79.9%)	75.8% (74.5%; 77.1%)	70.3% (67.1%; 73.7%)	
	IV	8,851	62.4% (61.3%; 63.4%)	43.3% (42.2%; 44.4%)	31.1% (30.1%; 32.2%)	23.8% (22.8%; 24.9%)	19.5% (18.5%; 20.6%)	11.5% (10.1%; 13.0%)	
	X/NA	1,449	55.8% (53.1%; 58.6%)	45.9% (43.1%; 48.9%)	40.0% (37.1%; 43.2%)	36.2% (33.0%; 39.7%)	34.1% (30.8%; 37.8%)	28.4% (23.7%; 33.9%)	
Colon	All	29,526	85.6% (85.2%; 86.1%)	79.4% (78.8%; 80.0%)	75.1% (74.4%; 75.7%)	71.8% (71.1%; 72.6%)	69.9% (69.0%; 70.8%)	63.4% (58.6%; 68.6%)	
	I	7,405	96.6% (96.0%; 97.2%)	95.9% (95.1%; 96.7%)	95.0% (93.9%; 96.0%)	93.8% (92.5%; 95.1%)	93.4% (91.8%; 95.0%)	87.9% (83.5%; 92.6%)	
	II	8,237	94.3% (93.6%; 95.0%)	93.2% (92.3%; 94.1%)	91.8% (90.6%; 93.0%)	90.3% (88.9%; 91.8%)	89.9% (88.2%; 91.7%)	78.1% (64.3%; 95.0%)	
	III	7,023	91.0% (90.2%; 91.9%)	85.0% (83.9%; 86.1%)	80.3% (78.9%; 81.6%)	76.2% (74.6%; 77.7%)	72.7% (70.9%; 74.5%)	70.1% (65.5%; 75.0%)	
	IV	6,386	60.3% (59.0%; 61.6%)	41.5% (40.2%; 42.8%)	29.9% (28.6%; 31.2%)	23.0% (21.7%; 24.2%)	18.8% (17.6%; 20.1%)	11.4% (9.7%; 13.4%)	
	X/NA	943	54.1% (50.7%; 57.6%)	42.9% (39.5%; 46.6%)	38.1% (34.6%; 42.0%)	33.6% (29.9%; 37.9%)	31.5% (27.7%; 35.9%)	27.0% (21.1%; 34.6%)	
Rectum	All	13,586	88.0% (87.4%; 88.7%)	81.4% (80.6%; 82.2%)	76.3% (75.3%; 77.2%)	72.0% (71.0%; 73.1%)	69.6% (68.4%; 70.8%)	63.0% (60.2%; 65.9%)	
	I	3,333	96.2% (95.3%; 97.2%)	94.8% (93.6%; 96.1%)	93.7% (92.2%; 95.3%)	92.4% (90.6%; 94.3%)	91.5% (89.2%; 93.8%)	95.9% (88.8%; 103.5%)	
	II	2,140	90.5% (89.0%; 92.1%)	86.5% (84.5%; 88.5%)	82.7% (80.3%; 85.1%)	78.1% (75.4%; 80.9%)	75.7% (72.6%; 79.0%)	64.5% (57.0%; 73.0%)	
	III	5,107	94.6% (93.8%; 95.4%)	90.0% (88.9%; 91.1%)	86.2% (84.9%; 87.6%)	82.1% (80.5%; 83.8%)	79.8% (77.9%; 81.6%)	69.9% (65.5%; 74.5%)	
	IV	2,507	67.6% (65.7%; 69.6%)	47.9% (45.9%; 50.1%)	34.2% (32.2%; 36.4%)	26.0% (24.0%; 28.1%)	21.3% (19.4%; 23.3%)	11.7% (9.6%; 14.2%)	
	X/NA	510	59.0% (54.6%; 63.7%)	51.3% (46.6%; 56.5%)	43.4% (38.3%; 49.1%)	40.7% (35.1%; 47.2%)	38.9% (33.1%; 45.8%)	30.7% (24.3%; 38.7%)	
Females									
CRC	All	34,972	85.2% (84.8%; 85.6%)	79.0% (78.5%; 79.6%)	75.3% (74.7%; 75.9%)	72.9% (72.2%; 73.5%)	71.4% (70.6%; 72.2%)	67.9% (65.6%; 70.4%)	

Net Survival Probability, 2015-2024									
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	I	7,964	97.8% (97.2%; 98.3%)	97.1% (96.4%; 97.8%)	96.6% (95.7%; 97.5%)	96.3% (95.1%; 97.4%)	95.8% (94.4%; 97.3%)	96.0% (91.1%; 101.2%)	
	II	9,317	93.6% (92.9%; 94.2%)	92.5% (91.7%; 93.4%)	91.2% (90.2%; 92.3%)	90.3% (89.0%; 91.6%)	89.3% (87.7%; 91.0%)	84.1% (78.7%; 89.9%)	
	III	9,829	90.4% (89.7%; 91.1%)	85.0% (84.1%; 85.9%)	81.3% (80.3%; 82.4%)	78.1% (76.9%; 79.4%)	76.7% (75.3%; 78.1%)	73.1% (68.3%; 78.4%)	
	IV	7,127	58.0% (56.8%; 59.2%)	39.2% (38.0%; 40.4%)	29.1% (28.0%; 30.3%)	23.3% (22.2%; 24.4%)	19.6% (18.5%; 20.7%)	13.7% (12.1%; 15.5%)	
	X/NA	1,306	58.6% (55.7%; 61.6%)	45.7% (42.7%; 49.0%)	39.5% (36.4%; 43.0%)	36.6% (33.2%; 40.2%)	35.7% (32.2%; 39.6%)	33.4% (28.2%; 39.6%)	
Colon	All	26,778	84.6% (84.1%; 85.1%)	78.6% (78.0%; 79.2%)	75.2% (74.5%; 75.9%)	73.0% (72.2%; 73.8%)	71.7% (70.8%; 72.6%)	69.3% (66.5%; 72.4%)	
	I	6,037	97.6% (97.0%; 98.2%)	97.2% (96.4%; 98.0%)	96.8% (95.7%; 97.9%)	96.5% (95.2%; 97.8%)	95.8% (94.1%; 97.5%)	96.9% (91.2%; 102.9%)	
	II	7,993	94.0% (93.3%; 94.7%)	93.5% (92.6%; 94.4%)	92.7% (91.6%; 93.8%)	92.2% (90.8%; 93.6%)	91.6% (89.9%; 93.4%)	87.3% (81.2%; 93.9%)	
	III	6,584	88.9% (88.0%; 89.8%)	83.1% (82.0%; 84.3%)	79.6% (78.2%; 80.9%)	76.7% (75.2%; 78.3%)	75.5% (73.7%; 77.4%)	73.7% (66.9%; 81.2%)	
	IV	5,668	57.0% (55.7%; 58.4%)	38.0% (36.7%; 39.4%)	28.4% (27.2%; 29.8%)	22.8% (21.6%; 24.1%)	19.5% (18.2%; 20.8%)	14.3% (12.4%; 16.4%)	
	X/NA	896	56.7% (53.3%; 60.4%)	43.5% (39.9%; 47.5%)	37.5% (33.7%; 41.6%)	34.1% (30.3%; 38.5%)	33.0% (28.9%; 37.6%)	33.3% (27.3%; 40.5%)	
Rectum	All	8,452	87.1% (86.3%; 87.9%)	80.5% (79.5%; 81.5%)	75.7% (74.6%; 76.9%)	72.3% (71.0%; 73.6%)	70.3% (68.9%; 71.8%)	63.3% (59.9%; 66.9%)	
	I	1,960	98.1% (97.1%; 99.1%)	96.8% (95.4%; 98.2%)	95.8% (94.0%; 97.6%)	95.6% (93.3%; 97.8%)	96.0% (93.4%; 98.7%)	93.3% (84.1%; 103.6%)	
	II	1,338	90.7% (88.9%; 92.7%)	86.5% (84.1%; 89.0%)	82.8% (79.8%; 85.8%)	78.7% (75.3%; 82.3%)	76.0% (72.1%; 80.2%)	64.5% (55.9%; 74.6%)	
	III	3,270	93.5% (92.5%; 94.6%)	88.8% (87.4%; 90.2%)	84.6% (83.0%; 86.3%)	80.8% (78.9%; 82.7%)	78.8% (76.7%; 81.1%)	71.7% (66.7%; 77.0%)	
	IV	1,473	61.7% (59.2%; 64.4%)	43.6% (41.0%; 46.3%)	31.6% (29.1%; 34.3%)	25.2% (22.8%; 27.9%)	20.3% (18.0%; 22.9%)	11.8% (9.3%; 15.0%)	
	X/NA	415	62.4% (57.5%; 67.8%)	50.4% (45.1%; 56.4%)	43.9% (38.4%; 50.2%)	41.6% (35.8%; 48.3%)	41.2% (35.1%; 48.2%)	33.7% (24.7%; 45.9%)	

5. CANCER SURVIVAL TRENDS



5.1. Colorectal cancer survival trends: by tumour stage

5.1.1. Colorectal cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	All	25,139	83.2% (82.7%; 83.7%)	69.7% (69.0%; 70.4%)	63.3% (62.4%; 64.1%)	21,131	82.5% (81.9%; 83.0%)	70.4% (69.7%; 71.2%)	65.4% (64.5%; 66.3%)
	I	3,921	95.3% (94.4%; 96.2%)	93.8% (92.4%; 95.3%)	91.2% (89.2%; 93.3%)	3,073	97.2% (96.3%; 98.2%)	97.1% (95.7%; 98.6%)	96.0% (93.9%; 98.2%)
	II	6,787	92.7% (91.9%; 93.5%)	87.7% (86.4%; 88.9%)	83.7% (82.0%; 85.4%)	6,068	92.1% (91.3%; 93.0%)	88.0% (86.7%; 89.3%)	85.5% (83.8%; 87.3%)
	III	6,892	87.8% (86.9%; 88.7%)	73.7% (72.3%; 75.0%)	65.1% (63.6%; 66.7%)	5,817	86.6% (85.6%; 87.6%)	72.8% (71.4%; 74.2%)	64.8% (63.2%; 66.5%)
	IV	4,478	63.2% (61.7%; 64.7%)	27.3% (25.9%; 28.8%)	15.8% (14.5%; 17.2%)	3,459	59.4% (57.8%; 61.2%)	25.1% (23.7%; 26.7%)	15.8% (14.5%; 17.2%)
	X/NA	3,446	67.2% (65.5%; 68.9%)	53.7% (51.7%; 55.8%)	49.4% (47.2%; 51.7%)	2,982	66.5% (64.7%; 68.4%)	55.4% (53.3%; 57.6%)	51.5% (49.2%; 54.0%)
2010-2014	All	23,761	85.9% (85.4%; 86.4%)	74.0% (73.3%; 74.7%)	68.0% (67.1%; 68.8%)	18,865	84.4% (83.8%; 85.0%)	72.5% (71.7%; 73.3%)	68.6% (67.7%; 69.6%)
	I	4,914	96.6% (95.8%; 97.4%)	94.6% (93.4%; 95.9%)	93.0% (91.3%; 94.8%)	3,505	97.1% (96.2%; 97.9%)	95.4% (94.0%; 96.8%)	93.7% (91.8%; 95.6%)
	II	6,078	93.3% (92.5%; 94.2%)	89.5% (88.2%; 90.9%)	85.7% (83.9%; 87.5%)	5,226	92.5% (91.6%; 93.5%)	88.9% (87.5%; 90.3%)	87.2% (85.4%; 89.1%)
	III	6,981	91.7% (90.9%; 92.5%)	80.3% (79.1%; 81.6%)	73.6% (72.1%; 75.2%)	5,569	89.5% (88.5%; 90.4%)	76.7% (75.3%; 78.1%)	72.5% (70.8%; 74.2%)
	IV	4,448	63.9% (62.5%; 65.5%)	31.1% (29.7%; 32.6%)	17.6% (16.4%; 18.9%)	3,334	60.2% (58.5%; 61.9%)	28.0% (26.4%; 29.6%)	18.6% (17.2%; 20.1%)
	X/NA	1,797	63.2% (60.8%; 65.6%)	45.3% (42.6%; 48.1%)	39.7% (36.8%; 42.8%)	1,534	61.4% (58.9%; 64.1%)	45.5% (42.7%; 48.6%)	40.8% (37.8%; 44.0%)
2015-2019	All	22,208	86.8% (86.3%; 87.3%)	76.5% (75.8%; 77.2%)	71.0% (70.1%; 71.9%)	18,079	85.0% (84.4%; 85.6%)	74.8% (74.0%; 75.6%)	71.0% (70.0%; 72.0%)
	I	5,566	96.7% (96.0%; 97.4%)	95.5% (94.3%; 96.6%)	94.1% (92.5%; 95.7%)	4,110	98.2% (97.5%; 98.9%)	96.9% (95.7%; 98.2%)	96.2% (94.4%; 98.0%)
	II	5,428	93.6% (92.7%; 94.5%)	90.7% (89.3%; 92.1%)	88.2% (86.3%; 90.2%)	4,801	93.3% (92.3%; 94.2%)	90.7% (89.2%; 92.2%)	88.8% (86.8%; 90.9%)

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	6,313	93.2% (92.4%; 94.0%)	84.0% (82.8%; 85.3%)	76.6% (75.0%; 78.2%)	5,068	90.3% (89.3%; 91.3%)	80.8% (79.3%; 82.2%)	76.2% (74.5%; 78.1%)
	IV	4,338	62.9% (61.4%; 64.5%)	30.7% (29.2%; 32.2%)	19.1% (17.8%; 20.5%)	3,508	57.7% (56.0%; 59.4%)	27.5% (25.9%; 29.1%)	18.4% (17.0%; 19.8%)
	X/NA	955	56.0% (52.8%; 59.5%)	40.4% (36.8%; 44.3%)	34.9% (31.0%; 39.3%)	867	57.0% (53.5%; 60.7%)	37.9% (34.1%; 42.0%)	34.5% (30.6%; 38.8%)
2020-2024	All	20,484	86.0% (85.4%; 86.5%)	74.3% (73.5%; 75.1%)	68.5% (67.3%; 69.7%)	16,990	85.4% (84.8%; 86.0%)	76.0% (75.1%; 76.9%)	71.6% (70.3%; 72.9%)
	I	5,107	96.2% (95.5%; 97.0%)	93.5% (92.2%; 94.9%)	91.1% (88.8%; 93.5%)	3,864	97.3% (96.5%; 98.1%)	96.2% (94.8%; 97.6%)	95.3% (92.8%; 97.8%)
	II	4,931	93.4% (92.4%; 94.3%)	88.8% (87.2%; 90.4%)	84.8% (82.0%; 87.6%)	4,527	93.9% (93.0%; 94.9%)	91.9% (90.4%; 93.5%)	90.1% (87.4%; 92.9%)
	III	5,771	91.9% (91.1%; 92.8%)	81.3% (79.9%; 82.8%)	75.3% (73.1%; 77.5%)	4,770	90.5% (89.6%; 91.5%)	81.9% (80.4%; 83.5%)	76.7% (74.3%; 79.3%)
	IV	4,514	61.8% (60.4%; 63.3%)	31.7% (30.2%; 33.3%)	20.3% (18.6%; 22.1%)	3,621	58.3% (56.7%; 60.0%)	31.0% (29.3%; 32.7%)	21.0% (19.1%; 23.0%)
	X/NA	494	55.3% (50.8%; 60.3%)	39.6% (34.5%; 45.3%)	32.3% (26.5%; 39.5%)	439	61.7% (56.9%; 66.9%)	42.8% (37.2%; 49.2%)	35.8% (28.6%; 44.8%)

5.2. Colorectal cancer survival trends: by sub-location and tumour stage

5.2.1. Colorectal cancer survival trends by sub-location, stage and sex: number at risk and net survival probabilities, 2004-2024

Period	sub-location	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	Colon	All	17,214	81.9% (81.2%; 82.5%)	68.8% (68.0%; 69.7%)	62.9% (61.9%; 64.0%)	15,714	81.5% (80.8%; 82.2%)	69.8% (68.9%; 70.7%)	65.6% (64.5%; 66.7%)
		I	2,495	94.6% (93.4%; 95.8%)	93.3% (91.4%; 95.2%)	91.4% (88.8%; 94.0%)	2,061	97.3% (96.2%; 98.5%)	97.8% (96.0%; 99.6%)	97.0% (94.4%; 99.7%)
		II	5,013	93.1% (92.2%; 94.1%)	89.0% (87.5%; 90.5%)	85.8% (83.8%; 87.8%)	4,926	92.1% (91.2%; 93.1%)	89.1% (87.7%; 90.5%)	87.7% (85.8%; 89.7%)
		III	4,269	85.4% (84.2%; 86.6%)	70.6% (68.9%; 72.4%)	62.2% (60.2%; 64.2%)	4,017	84.6% (83.4%; 85.9%)	70.4% (68.7%; 72.2%)	63.3% (61.3%; 65.4%)
		IV	3,242	60.8% (59.0%; 62.5%)	26.4% (24.8%; 28.1%)	15.1% (13.5%; 16.8%)	2,701	57.4% (55.5%; 59.4%)	23.6% (21.9%; 25.3%)	15.2% (13.8%; 16.7%)
		X/NA	2,428	67.1% (65.1%; 69.1%)	55.4% (53.1%; 57.9%)	51.8% (49.1%; 54.6%)	2,201	67.2% (65.1%; 69.3%)	56.3% (53.8%; 58.9%)	52.7% (50.0%; 55.7%)
	Rectum	All	8,143	86.0% (85.1%; 86.8%)	71.4% (70.2%; 72.6%)	63.9% (62.5%; 65.4%)	5,529	85.2% (84.2%; 86.3%)	72.2% (70.7%; 73.6%)	64.7% (63.0%; 66.4%)
		I	1,445	96.4% (95.0%; 97.8%)	94.9% (92.6%; 97.2%)	91.0% (87.9%; 94.3%)	1,023	96.8% (95.3%; 98.4%)	95.6% (93.1%; 98.1%)	93.8% (90.2%; 97.5%)
		II	1,783	91.5% (89.9%; 93.1%)	83.9% (81.5%; 86.4%)	77.6% (74.6%; 80.7%)	1,152	92.1% (90.3%; 94.1%)	82.9% (80.0%; 85.9%)	75.6% (72.0%; 79.5%)
		III	2,644	91.5% (90.2%; 92.8%)	78.3% (76.3%; 80.4%)	69.5% (67.1%; 72.0%)	1,808	91.2% (89.6%; 92.7%)	78.0% (75.7%; 80.4%)	68.0% (65.3%; 70.9%)
		IV	1,244	69.4% (66.7%; 72.1%)	29.6% (27.0%; 32.4%)	17.6% (15.4%; 20.1%)	761	66.6% (63.2%; 70.2%)	30.6% (27.4%; 34.3%)	17.8% (15.0%; 21.1%)
		X/NA	1,028	67.3% (64.3%; 70.5%)	49.4% (45.9%; 53.3%)	43.5% (39.7%; 47.6%)	785	64.4% (60.9%; 68.1%)	52.6% (48.7%; 57.0%)	47.8% (43.5%; 52.6%)
2010-2014	Colon	All	16,426	84.9% (84.3%; 85.6%)	73.3% (72.5%; 74.2%)	67.8% (66.7%; 68.8%)	14,228	84.0% (83.3%; 84.7%)	72.4% (71.4%; 73.3%)	69.1% (68.0%; 70.2%)
		I	3,432	96.8% (95.9%; 97.7%)	95.7% (94.3%; 97.2%)	94.2% (92.1%; 96.3%)	2,559	97.0% (96.0%; 98.0%)	95.1% (93.5%; 96.8%)	93.1% (90.9%; 95.5%)
		II	4,725	93.8% (92.9%; 94.8%)	91.0% (89.5%; 92.5%)	87.9% (85.8%; 89.9%)	4,371	93.3% (92.4%; 94.3%)	90.6% (89.1%; 92.2%)	89.9% (87.8%; 92.0%)
		III	4,059	90.0% (88.9%; 91.1%)	77.7% (76.0%; 79.5%)	71.1% (69.1%; 73.2%)	3,863	87.9% (86.7%; 89.1%)	74.5% (72.8%; 76.3%)	70.8% (68.8%; 72.9%)
		IV	3,231	62.0% (60.2%; 63.7%)	29.3% (27.7%; 31.1%)	16.8% (15.4%; 18.3%)	2,576	58.8% (56.9%; 60.8%)	26.5% (24.8%; 28.4%)	18.1% (16.6%; 19.8%)
		X/NA	1,267	61.9% (59.1%; 64.8%)	44.4% (41.3%; 47.8%)	38.7% (35.3%; 42.4%)	1,084	61.4% (58.3%; 64.6%)	45.5% (42.2%; 49.2%)	40.9% (37.3%; 44.8%)
	Rectum	All	7,602	88.0% (87.2%; 88.8%)	75.2% (74.0%; 76.5%)	68.0% (66.5%; 69.4%)	4,761	85.5% (84.4%; 86.7%)	72.8% (71.3%; 74.3%)	67.0% (65.2%; 68.8%)

Period	sub-location	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		I	1,518	96.0% (94.6%; 97.4%)	92.1% (89.8%; 94.4%)	90.0% (86.9%; 93.2%)	956	97.2% (95.7%; 98.8%)	96.3% (93.7%; 99.0%)	95.2% (91.6%; 98.9%)
		II	1,367	91.7% (89.9%; 93.6%)	84.7% (82.0%; 87.5%)	77.6% (74.1%; 81.2%)	861	88.6% (86.1%; 91.1%)	80.1% (76.7%; 83.6%)	73.5% (69.5%; 77.8%)
		III	2,945	94.1% (93.0%; 95.2%)	83.9% (82.2%; 85.7%)	77.1% (75.0%; 79.4%)	1,717	93.1% (91.7%; 94.6%)	81.5% (79.2%; 83.8%)	76.1% (73.4%; 78.9%)
		IV	1,237	69.3% (66.6%; 72.0%)	35.8% (33.0%; 38.8%)	19.9% (17.6%; 22.6%)	772	65.0% (61.6%; 68.6%)	32.7% (29.4%; 36.4%)	19.9% (17.1%; 23.2%)
		X/NA	537	65.5% (61.3%; 70.1%)	46.7% (42.1%; 51.9%)	41.4% (36.4%; 47.1%)	460	61.4% (56.7%; 66.4%)	44.8% (39.9%; 50.4%)	40.0% (34.9%; 45.9%)
2015-2019	Colon	All	15,374	86.0% (85.4%; 86.7%)	75.8% (74.9%; 76.7%)	70.8% (69.7%; 72.0%)	13,855	84.2% (83.5%; 84.9%)	74.3% (73.4%; 75.3%)	71.2% (70.0%; 72.3%)
		I	3,899	96.8% (95.9%; 97.6%)	95.4% (94.1%; 96.8%)	94.1% (92.2%; 96.1%)	3,114	97.9% (97.1%; 98.7%)	97.1% (95.7%; 98.5%)	96.1% (94.0%; 98.1%)
		II	4,293	94.3% (93.3%; 95.3%)	92.5% (91.0%; 94.1%)	91.2% (89.0%; 93.4%)	4,108	93.3% (92.3%; 94.3%)	91.4% (89.9%; 93.0%)	90.5% (88.3%; 92.8%)
		III	3,677	91.7% (90.6%; 92.8%)	81.5% (79.8%; 83.3%)	73.7% (71.5%; 75.9%)	3,423	88.9% (87.7%; 90.2%)	79.1% (77.2%; 80.9%)	75.4% (73.1%; 77.7%)
		IV	3,099	60.6% (58.9%; 62.5%)	28.5% (26.8%; 30.3%)	17.7% (16.2%; 19.3%)	2,805	56.0% (54.2%; 58.0%)	26.4% (24.7%; 28.2%)	18.0% (16.5%; 19.7%)
		X/NA	634	54.8% (50.8%; 59.1%)	39.0% (34.7%; 43.8%)	32.7% (28.2%; 37.9%)	592	55.3% (51.1%; 59.8%)	35.9% (31.5%; 40.8%)	32.3% (27.7%; 37.6%)
	Rectum	All	7,091	88.4% (87.5%; 89.3%)	77.7% (76.4%; 78.9%)	70.9% (69.4%; 72.5%)	4,349	87.7% (86.6%; 88.8%)	76.1% (74.5%; 77.7%)	70.5% (68.6%; 72.4%)
		I	1,703	96.4% (95.2%; 97.7%)	95.4% (93.4%; 97.4%)	93.3% (90.5%; 96.3%)	1,009	98.7% (97.4%; 100.0%)	96.5% (94.1%; 99.0%)	95.7% (92.5%; 99.1%)
		II	1,150	90.9% (88.9%; 93.0%)	84.0% (80.9%; 87.2%)	77.0% (73.2%; 81.1%)	698	92.8% (90.4%; 95.3%)	86.2% (82.3%; 90.3%)	78.7% (73.7%; 84.1%)
		III	2,660	95.2% (94.2%; 96.3%)	87.5% (85.7%; 89.4%)	80.6% (78.3%; 83.1%)	1,657	93.2% (91.7%; 94.7%)	84.1% (81.8%; 86.4%)	77.9% (75.1%; 80.8%)
		IV	1,259	68.2% (65.6%; 71.0%)	35.9% (33.1%; 38.9%)	22.4% (19.9%; 25.1%)	708	64.2% (60.7%; 68.0%)	31.8% (28.4%; 35.7%)	19.9% (17.0%; 23.3%)
		X/NA	323	58.5% (53.0%; 64.5%)	42.8% (36.7%; 49.9%)	38.9% (32.0%; 47.4%)	279	60.5% (54.5%; 67.1%)	41.9% (35.4%; 49.6%)	38.8% (31.9%; 47.1%)
2020-2024	Colon	All	14,224	85.2% (84.5%; 85.9%)	74.1% (73.2%; 75.1%)	68.7% (67.2%; 70.2%)	12,991	85.0% (84.3%; 85.7%)	76.2% (75.2%; 77.2%)	71.9% (70.3%; 73.5%)
		I	3,515	96.3% (95.4%; 97.3%)	94.4% (92.8%; 96.0%)	92.3% (89.5%; 95.2%)	2,931	97.3% (96.4%; 98.2%)	96.5% (94.9%; 98.2%)	95.3% (92.4%; 98.3%)
		II	3,957	94.3% (93.2%; 95.3%)	90.8% (89.1%; 92.6%)	87.7% (84.5%; 90.9%)	3,894	94.8% (93.9%; 95.8%)	94.1% (92.5%; 95.7%)	92.8% (89.8%; 95.9%)
		III	3,349	90.3% (89.1%; 91.5%)	78.7% (76.7%; 80.7%)	72.0% (68.9%; 75.1%)	3,167	88.8% (87.5%; 90.1%)	80.2% (78.3%; 82.2%)	74.9% (71.6%; 78.4%)
		IV	3,288	60.0% (58.2%; 61.7%)	31.5% (29.7%; 33.4%)	20.5% (18.5%; 22.7%)	2,865	58.0% (56.1%; 59.9%)	30.7% (28.9%; 32.7%)	20.9% (18.8%; 23.2%)
		X/NA	309	52.6% (46.9%; 59.0%)	36.6% (30.6%; 43.7%)	28.5% (21.6%; 37.6%)	304	59.6% (53.8%; 66.0%)	40.2% (33.6%; 48.2%)	31.7% (23.1%; 43.5%)

Period	sub-location	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	Rectum	All	6,497	87.7% (86.8%; 88.6%)	74.4% (73.0%; 75.8%)	67.8% (65.9%; 69.8%)	4,103	86.4% (85.3%; 87.6%)	75.3% (73.6%; 77.0%)	70.4% (68.2%; 72.7%)
		I	1,630	96.0% (94.7%; 97.3%)	91.6% (89.2%; 94.0%)	88.4% (84.6%; 92.3%)	951	97.2% (95.7%; 98.7%)	95.0% (92.3%; 97.7%)	95.2% (91.0%; 99.6%)
		II	990	90.0% (87.8%; 92.4%)	80.7% (77.1%; 84.4%)	73.1% (67.7%; 79.0%)	640	88.2% (85.3%; 91.2%)	78.8% (74.5%; 83.4%)	73.7% (67.6%; 80.3%)
		III	2,447	93.9% (92.7%; 95.1%)	84.6% (82.6%; 86.7%)	79.2% (76.4%; 82.2%)	1,613	93.9% (92.4%; 95.3%)	85.1% (82.7%; 87.6%)	80.1% (76.8%; 83.6%)
		IV	1,248	67.0% (64.3%; 69.8%)	32.3% (29.4%; 35.4%)	20.0% (17.1%; 23.5%)	765	59.4% (55.9%; 63.1%)	31.9% (28.4%; 35.8%)	21.3% (17.6%; 25.9%)
		X/NA	187	59.8% (52.7%; 67.8%)	44.7% (36.4%; 54.9%)	39.1% (29.8%; 51.2%)	136	66.3% (58.3%; 75.5%)	48.2% (38.7%; 60.0%)	44.8% (34.2%; 58.7%)

6. CANCER MORTALITY



6.1. Colorectal cancer mortality: by region

6.1.1. Colorectal cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Males																						
Belgium	0	0	0	0	0	0	1	4	9	24	25	64	104	148	177	228	191	198	125	22	1,320	25.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[1.1]	[2.3]	[6.4]	[6.3]	[15.9]	[27.8]	[46.5]	[66.5]	[112.2]	[152.9]	[248.3]	[399.0]	[363.0]	[22.9]	(24.3; 27.1)
Brussels	0	0	0	0	0	0	0	2	3	2	4	8	6	9	11	23	10	15	9	3	105	29.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[4.3]	[6.5]	[4.5]	[9.8]	[22.6]	[20.8]	[42.1]	[65.4]	[182.2]	[124.3]	[299.8]	[390.8]	[559.7]	[17.3]	(23.5; 34.9)
Flanders	0	0	0	0	0	0	0	1	2	16	17	35	54	78	97	128	120	128	85	14	775	23.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.9]	[7.6]	[7.4]	[14.4]	[23.6]	[39.8]	[59.1]	[98.2]	[145.6]	[237.9]	[408.6]	[352.6]	[23.1]	(22.1; 25.4)
Wallonia	0	0	0	0	0	0	1	1	4	6	4	21	44	61	69	77	61	55	31	5	440	28.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.9]	[3.4]	[5.1]	[3.2]	[16.8]	[37.6]	[60.5]	[80.8]	[127.7]	[177.3]	[262.8]	[376.9]	[321.8]	[24.4]	(26.0; 31.5)
Females																						
Belgium	0	0	0	0	1	0	3	6	12	17	24	41	50	88	110	157	173	215	156	57	1,110	15.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.8]	[1.6]	[3.1]	[4.6]	[6.2]	[10.3]	[13.1]	[26.0]	[37.0]	[63.9]	[99.3]	[160.7]	[220.1]	[273.8]	[18.7]	(14.7; 16.6)
Brussels	0	0	0	0	1	0	0	3	0	2	3	3	3	8	11	11	10	12	16	4	87	15.8
	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[0.0]	[0.0]	[6.3]	[0.0]	[4.9]	[7.8]	[8.8]	[9.9]	[32.0]	[51.3]	[61.1]	[77.8]	[122.4]	[282.1]	[192.1]	[13.7]	(12.4; 19.2)

Region	N [CR]																					ESR2013 (95%CI)
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	0	0	0	0	2	3	8	9	17	23	21	55	54	81	85	124	82	30	594	13.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[1.4]	[3.6]	[4.3]	[7.6]	[9.7]	[9.2]	[27.2]	[30.8]	[53.9]	[77.7]	[145.3]	[186.4]	[244.8]	[17.4]	(12.6; 14.8)
Wallonia	0	0	0	0	0	0	1	0	4	6	4	15	26	25	45	65	78	79	58	23	429	19.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.0]	[3.4]	[5.1]	[3.2]	[11.9]	[21.1]	[22.4]	[45.0]	[83.9]	[150.2]	[204.3]	[273.7]	[354.7]	[22.8]	(17.6; 21.3)

7. CANCER MORTALITY TRENDS



7.1. Colorectal cancer mortality trends: by region

7.1.1. Colorectal cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	N	1,440	1,529	1,493	1,528	1,567	1,544	1,580	1,546	1,572	1,493	1,442	1,530	1,474	1,514	1,356	1,349	1,323	1,324	1,357	1,320		
	CR	28.3	29.9	29.0	29.5	30.0	29.3	29.7	28.8	29.0	27.4	26.3	27.8	26.6	27.2	24.2	24.0	23.4	23.3	23.8	22.9		
	ESR2013	41.0	44.2	41.6	40.2	41.1	39.5	39.4	37.7	37.6	35.9	33.1	34.3	32.5	32.3	28.4	28.0	26.9	26.7	26.6	25.7	-2.8 (-3.0; -2.5)	2004-2023
																						-1.5 (-2.3; -0.8)	2004-2011
																						-3.5 (-3.9; -3.1)	2012-2023
Brussels	N	109	128	116	128	105	136	123	127	120	109	106	109	115	132	113	110	105	111	104	105		
	CR	22.7	26.5	23.7	25.8	20.8	26.3	23.3	23.4	21.7	19.4	18.7	19.0	19.8	22.7	19.3	18.6	17.6	18.5	17.3	17.3		
	ESR2013	37.7	43.3	38.6	41.4	32.1	42.7	39.4	38.4	37.2	33.3	31.6	33.2	32.5	38.1	31.8	32.2	27.8	31.9	29.6	29.2	-1.7 (-2.4; -1.1)	2004-2023
Flanders	N	918	949	954	922	909	973	983	958	984	908	858	968	884	881	798	780	760	742	769	775		
	CR	30.9	31.8	31.8	30.6	29.9	31.8	31.9	30.8	31.4	28.8	27.1	30.4	27.6	27.3	24.6	23.9	23.2	22.5	23.2	23.1		
	ESR2013	43.2	44.9	43.6	39.8	39.7	40.3	39.7	38.0	38.1	35.2	31.9	34.7	31.2	29.9	26.8	25.6	24.5	23.8	23.8	23.8	-3.5 (-3.8; -3.2)	2004-2023
																						-1.9 (-2.9; -0.9)	2004-2011
																						-4.4 (-5.0; -3.9)	2012-2023
Wallonia	N	413	452	423	478	553	435	474	461	468	476	478	453	475	501	445	459	458	471	484	440		
	CR	25.2	27.4	25.5	28.7	33.0	25.8	27.9	26.9	27.1	27.4	27.4	25.9	27.0	28.4	25.1	25.8	25.7	26.4	27.0	24.4		

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
ESR2013	37.1	42.9	38.6	40.3	46.8	37.0	38.6	37.3	36.5	38.4	36.1	33.8	35.1	36.0	31.1	32.0	31.6	32.1	31.7	28.8	-1.7 (-2.2; -1.2)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Colorectal cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	
Belgium	N	1,386	1,390	1,415	1,414	1,396	1,490	1,348	1,385	1,401	1,372	1,315	1,278	1,268	1,313	1,254	1,278	1,199	1,097	1,102	1,110			
	CR	26.1	26.1	26.4	26.2	25.7	27.2	24.4	24.8	24.9	24.3	23.2	22.4	22.1	22.8	21.7	22.0	20.6	18.8	18.8	18.7			
	ESR2013	26.0	25.9	25.6	25.2	24.4	25.9	22.5	22.9	22.8	22.0	20.8	19.9	19.6	19.9	18.8	18.8	17.2	15.8	15.7	15.6	-2.8 (-3.0; -2.5)	2004-2023	
																							-1.9 (-2.6; -1.2)	2004-2012
																							-3.4 (-3.9; -3.0)	2013-2023
Brussels	N	138	133	151	117	129	140	124	123	121	113	118	123	90	113	116	116	98	85	92	87			
	CR	26.6	25.4	28.5	21.9	23.8	25.3	22.0	21.3	20.6	19.1	19.8	20.4	14.8	18.5	19.0	18.8	15.8	13.7	14.8	13.7			
	ESR2013	25.5	25.1	27.9	21.5	24.4	26.5	22.1	22.1	21.4	20.1	20.3	22.4	16.4	20.0	21.5	21.2	17.5	15.5	16.6	15.8	-2.5 (-3.2; -1.7)	2004-2023	
Flanders	N	788	803	821	821	810	854	789	796	816	775	748	702	737	736	689	709	644	619	592	594			
	CR	25.8	26.2	26.6	26.5	25.9	27.2	24.9	24.9	25.4	24.0	23.1	21.5	22.5	22.3	20.8	21.3	19.2	18.4	17.5	17.4			
	ESR2013	25.9	26.2	25.8	25.5	24.5	25.4	22.6	22.6	22.7	21.2	20.1	18.5	18.9	18.6	17.1	17.3	15.2	14.5	13.8	13.7	-3.5 (-3.8; -3.3)	2004-2023	
																							-2.2 (-2.9; -1.5)	2004-2012
																							-4.5 (-5.0; -4.0)	2013-2023
Wallonia	N	460	454	443	476	457	496	435	466	464	484	449	453	441	464	449	453	457	393	418	429			
	CR	26.4	26.0	25.2	26.9	25.7	27.7	24.2	25.7	25.5	26.5	24.5	24.6	23.9	25.1	24.2	24.4	24.5	21.1	22.3	22.8			
	ESR2013	26.4	25.5	24.6	25.7	24.3	26.5	22.4	23.6	23.6	23.9	22.1	21.8	21.6	22.2	21.2	21.3	21.1	18.5	19.3	19.5	-1.6 (-1.9; -1.3)	2004-2023	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.2. Colorectal cancer mortality trends: by age group

7.2.1. Colorectal cancer mortality* trends in males, by age group: number of new diagnoses, crude and age-standardised mortality rates, including average annual percentage change, 2004-2024

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-39 N	9	8	6	11	16	10	11	6	9	3	5	9	7	11	9	7	10	9	11	5		
CR	0.5	0.5	0.3	0.6	0.9	0.6	0.6	0.3	0.5	0.2	0.3	0.5	0.4	0.6	0.5	0.4	0.6	0.5	0.6	0.3		
ESR2013	0.5	0.5	0.4	0.6	0.9	0.6	0.6	0.4	0.5	0.2	0.3	0.5	0.4	0.6	0.5	0.4	0.6	0.5	0.6	0.3	-0.7 (-3.7; 2.3)	2004-2023
40-49 N	38	24	32	37	40	41	28	28	34	29	26	26	31	38	17	23	28	27	26	33		
CR	4.8	3.0	4.0	4.6	4.9	5.0	3.4	3.4	4.2	3.6	3.2	3.3	4.0	4.9	2.2	3.0	3.7	3.6	3.4	4.4		
ESR2013	4.8	3.0	4.0	4.6	4.9	5.0	3.4	3.4	4.1	3.5	3.2	3.3	3.9	4.9	2.2	3.0	3.7	3.6	3.4	4.4	-1.1 (-2.7; 0.6)	2004-2023
50-74 N	676	691	665	670	667	655	697	663	658	647	618	676	637	632	568	572	547	559	605	518		
CR	50.1	50.6	48.1	47.9	47.0	45.4	47.5	44.3	43.2	41.9	39.4	42.3	39.2	38.2	33.8	33.6	31.8	32.2	34.7	29.5		
ESR2013	52.7	53.2	51.5	51.0	50.7	49.5	51.3	48.2	47.2	46.2	43.4	46.5	42.3	40.5	35.5	35.1	33.0	33.0	35.6	30.1	-2.9 (-3.2; -2.5)	2004-2023
																					-1.4 (-2.2; -0.6)	2004-2013
																					-4.2 (-4.9; -3.5)	2014-2023
75+ N	717	806	790	810	844	838	844	849	871	814	793	819	799	833	762	747	738	729	715	764		
CR	244.6	266.3	251.6	248.6	250.6	242.5	238.4	235.0	236.0	216.4	206.8	209.2	202.4	211.0	191.8	184.9	178.5	175.2	165.8	171.6		
ESR2013	270.7	307.0	283.3	267.0	277.1	264.1	259.2	252.2	252.0	238.9	217.1	219.0	212.5	214.1	192.3	187.7	181.3	179.5	168.9	177.3	-2.7 (-3.1; -2.4)	2004-2023
																					-0.1 (-2.7; 2.5)	2004-2007
																					-3.2 (-3.6; -2.8)	2008-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.2.2. Colorectal cancer mortality* trends in females, by age group: number of new diagnoses, crude and age-standardised mortality rates, including average annual percentage change, 2004-2024

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-39 N	9	6	7	18	4	13	8	6	7	4	13	6	9	10	13	14	8	14	17	10		
CR	0.5	0.4	0.4	1.1	0.2	0.8	0.5	0.3	0.4	0.2	0.8	0.3	0.5	0.6	0.7	0.8	0.5	0.8	1.0	0.6		
ESR2013	0.5	0.4	0.4	1.1	0.2	0.8	0.5	0.4	0.4	0.2	0.8	0.4	0.5	0.6	0.8	0.8	0.5	0.8	1.0	0.6	2.7 (-0.7; 6.3)	2004-2023
40-49 N	27	35	30	34	32	29	21	31	31	23	29	28	29	25	27	27	16	24	8	29		
CR	3.5	4.4	3.8	4.3	4.0	3.6	2.6	3.9	3.9	2.9	3.7	3.6	3.8	3.3	3.6	3.6	2.1	3.2	1.1	3.9		
ESR2013	3.5	4.5	3.8	4.3	4.0	3.6	2.6	3.9	3.9	2.9	3.7	3.6	3.8	3.3	3.6	3.6	2.1	3.2	1.1	3.9	-2.5 (-4.7; -0.2)	2004-2023
50-74 N	484	465	448	443	442	473	386	424	438	413	383	413	389	410	392	430	366	332	359	313		
CR	33.6	32.0	30.6	29.9	29.6	31.2	25.1	27.1	27.6	25.7	23.5	24.9	23.1	24.0	22.6	24.6	20.7	18.6	20.1	17.4		
ESR2013	33.1	31.9	30.7	30.3	30.2	32.1	25.9	28.2	28.6	27.0	24.6	26.1	24.2	24.8	23.0	24.7	20.7	18.5	19.9	17.2	-3.0 (-3.5; -2.5)	2004-2023
																					-2.0 (-2.9; -1.2)	2004-2015
																					-4.3 (-5.6; -3.1)	2016-2023
75+ N	866	884	930	919	918	975	933	924	925	932	890	831	841	868	822	807	809	726	718	758		
CR	166.6	166.5	170.8	164.9	161.2	168.6	159.0	155.7	154.2	154.2	145.8	134.7	136.4	141.7	134.5	131.4	130.4	117.3	113.3	117.4		
ESR2013	171.7	173.1	174.5	168.5	163.0	171.8	157.7	153.4	150.5	149.5	141.1	127.4	129.1	131.4	123.9	118.1	117.4	105.8	103.4	108.4	-2.7 (-3.0; -2.4)	2004-2023
																					-0.9 (-2.1; 0.2)	2004-2009
																					-3.3 (-3.7; -3.0)	2010-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026